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ABSTRACT 
 
Medulloblastoma is the most common brain tumor in children and one third of the 
patients remain incurable. Tumor metastasis is one of the primary reasons for its high 
mortality rate. Despite evidence of overexpression of PDGFRα and PDGFRβ in 
metastatic medulloblastoma, their individual roles remain controversial and equivocal. 
Analysis of their specific signaling pathway in medulloblastoma cells revealed that 
PDGFRα and PDGFRβ signaling events lead to distinct cellular functions: while 
PDGFRβ stimulated cell proliferation and invasion, the expression of CD44 to regulate 
progression via c-Myc and inhibited cell death, PDGFRα displayed the opposite effects. 
Studies also revealed that c-Myc plays an intermediary role by regulating the downstream 
molecules in PDGFRβ signal pathway such as CD44 and NFB. NFB activity was 
found to be down- regulated in the absence of PDGFRβ pathway, with its activity 
restored by the overexpression of c-Myc. Analysis of medulloblastoma patient tissues 
without a prior knowledge of their metastatic nature further confirmed that PDGFRβ-
CD44 axis regulate medulloblastoma metastasis. 
Co-inhibition studies performed by simultaneous inhibition of both PDGFRβ and c-
Myc either by using siRNAs or by using pharmacological inhibitors demonstrated an 
enhanced inhibitory effect on medulloblastoma cell proliferation and migration. Using 
miRNA profiling of Daoy cells lacking either PDGFRβ or c-Myc alone or both, a set of 
miRNAs regulated by both PDGFRβ and c-Myc in common were identified. Integrative 
analysis of these miRNAs and their targets revealed that activation of PDGFRβ signaling 
and overexpression of c-Myc may enhance medulloblastoma progression via modulating 
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the expression of several miRNAs such as miR-1280, -1260 and consequently regulating 
the expression of oncogenic molecules, such as Jagged 2 and CDC25A, respectively. 
Specific inhibition of miRNAs, miR-1280 and -1260, and JAG2 demonstrated their vital 
roles in medulloblastoma cell proliferation and migration.  
These findings suggest that the PDGFRβ-CD44 is a regulatory axis modulating 
medulloblastoma progression via c-Myc and targeting PDGFRβ/c-Myc/CD44 may 
provide a novel therapeutic strategy for the treatment of metastatic medulloblastoma. 
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CHAPTER 1. INTRODUCTION 
1.1. Medulloblastoma (MB) 
 
MB is a highly malignant childhood brain tumor comprising 20% of all pediatric 
central nervous system (CNS) tumors and 40% of all cerebellar tumors [1-3]. Every 9.6 
children per million is estimated to be affected by MB [4]. Despite the advances in its 
diagnosis and treatment, MB still remains a common malignant tumor responsible for 
significant (~10%) childhood morbidity and mortality with an overall 5-year survival 
rates for children to be just around 60% [4, 5]. One of the primary causes for significant 
mortality rates in children with MB is the metastasis of the tumor. Approximately 30-
35% of the children have disseminated disease at the time of clinical presentation [6, 7]. 
Metastasis occurs along the spinal cord and later spreads to other organs like bone 
marrow, lungs, bones and lymph nodes [8]. No specific therapy for the treatment for 
metastatic MB is available till date. Deciphering signal pathways and molecular 
mechanisms that regulate MB might provide crucial therapeutic targets and strategies in 
the treatment of metastatic MB. 
1.1.1. MB history 
 
 World Health Organization (WHO) has categorized MB as a grade 4 tumor that 
consist of highly aggressive type of cells [9]. James Homer Wright, a pathologist at 
Massachusetts General Hospital, Boston was the person who first described MB in 1910 
as neurocytoma as it resembled neuroblastoma [10-12]. Based on the observation from 
the tumor tissue, he elucidated MB as a rosette, which is a characteristic feature of classic 
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MB, a variant of MB. In 1897, Shaper put forth his views about MB origin indicating that 
MB originated from a hypothetical multipotential cell called as “Medulloblast”, which 
was believed to be one of the cells that populated primitive neural tumor [13]. Later in 
1925, Bailey and Cushing coined the term “Medulloblastoma” favoring MB derivation 
from medulloblast and described it as a highly malignant glioma arising in the cerebellum 
or fourth ventricle and had the tendency to extend to other parts of the CNS [9, 10, 14, 
15]. Cushing performed numerous operations on MB patients and studied their 
characteristic clinical, pathological and epidemiological features. Cushing experimented 
in various ways to treat MB patients; however, all patients died except one, named Jack 
Hagan, who survived for five years post incomplete resection. The treatment regimen that 
was administered to this patient consisted of three treatments of cranial irradiation 
followed by posterior fossa resection thrice, to ensure and limit recurrence of the local 
disease. Eventually, he died because of spinal metastasis. The success of saving his 
patient for comparatively prolonged period of time was sufficient for Cushing to believe 
that MB could be treated [13].  
1.1.2. MB cells of origin 
Studies have indicated that MB arises from neuroepithelial stem cells differentiating 
along glial and neuronal pathways  present in or near the cerebellum (Figure 1A) [16]. 
Evidence now postulates a close relationship between the normal development of 
cerebellum and the initiation of MB. Cerebellum is a part of the brain structure which 
takes almost seven months after birth to be mature, and this prolonged maturation period 
increases the chances for abnormalities during development [17, 18]. Aberrations arising 
in cell differentiation and signal pathways that produce different elements of cerebellum 
have been indicated to trigger the induction of MB [14, 18].  
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The process of normal cerebellum development involves two specific germinal zones 
that give rise to the cells of the cerebellum – primary germinal zone and the nuclear 
transitory zone [19]. Primary zone consists of Purkinje cells and interneurons that are 
precursor cells of gamma-aminobutyric acid (GABAergic) neurons which are positioned 
above the IV ventricle [20, 21]. Nuclear transitory zone assists in the migration of 
glutamatergic neurons located in the deep cerebellar nuclei to rise within the rhombic lip 
[22]. The external germinal layer (EGL) is formed when the granule neuron precursor 
(GNP) cells, which also rise from the rhombic lip, migrate across the cerebellar anlage. 
The internal granule layer (IGL) is formed when granule neuron precursor cells 
proliferate inside the EGL and later migrate inwards (Figure 1B) [16, 19].  
Numerous signaling pathways have been demonstrated to play critical roles in the 
development of cerebellum. Sonic hedgehog (SHH) pathway with its receptor patched 
(PTC) is known to be expressed by neuronal precursors in the EGL [23, 24]. Similarly, 
other molecules like neurotrophils such as p75
NTR
 and brain-derived neurotrophic factor 
(BDNF) along with its receptor tyrosine related kinase B (trkB), have been shown to be 
involved in EGL cell divisions; studies have also shown that neurotropin-3 (NT3) and its 
receptor trkC might have a crucial role in the terminal differentiation of EGL cells into 
IGL neurons [25-27].  Notably in MB, the expression of trkC is a potential marker for 
good prognosis [16, 28, 29].  
Studies performed recently have disclosed numerous other gene mutations that play a 
crucial role in cerebellar developmental process that trigger MB origination when 
deregulated [30]. PI3K/Akt signaling pathway promotes growth and survival of neuronal 
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Figure 1. Precursor cell populations in normal mature cerebellum development and MB 
location. A) Location of MB formation in brain. B) The normal cerebellum development 
is made up of two germinal zones - primary germinal zone and the nuclear transitory 
zone. Primary zone consists of gamma-aminobutyric acid ergic neurons and nuclear 
transitory zone assists in the migration of glutamatergic neurons located in the deep 
cerebellar nuclei to rise within the rhombic lip. The IGL is formed when granule neuron 
precursor cells proliferate inside the EGL and later migrate inwards [14, 16, 19].  
A 
B 
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precursor cells during the normal cerebellum development. Animal studies on PTEN, a 
negative regulator of PI3K/Akt signaling pathway, which when deleted have 
demonstrated abnormalities in the cerebellar tissues [31]. Similarly, complete absence in 
the formation of cerebellum in animal models was observed in the presence of Wnt-1 
proto-oncogene mutants [32, 33]. In addition, β-catenin which is a vital molecule 
regulating the canonical WNT pathway, when deleted, has been shown to produce 
abnormalities in mice cerebellar morphogenesis [34]. 
1.1.3. MB signaling pathways 
 
Studies performed in genetically engineered in vivo models of MB provide evidence 
indicating that signal pathways play a very crucial role in the initiation of MB by 
promoting proliferation and differentiation of neural progenitor cells during normal 
cerebellar development [35]. Mutations in molecules involved in pathways such Sonic-
Hedgehog-Patched, Notch, and Wnt have been shown to play an important role in the 
induction of MB [36-38].  
1.1.3.1. Sonic hedgehog signaling 
 
Sonic hedgehog (SHH) signaling plays a crucial role in the growth and development 
of the cerebellum by regulating both progenitor and stem cells in the CNS [39-41]. SHH 
signaling is initiated by three ligands namely Sonic hedgehog (SHH), Indian hedgehog 
(IHH) and Dessert hedgehog (DHH) [41]. The ligand has a receptor complex comprising 
of a twelve-pass transmembrane protein called Patched (PTCH) with a characteristic 
transporter-like structure, which is secreted by the Purkinje cells present below (a) EGL 
and (b) Smoothened (SMO), [24, 42, 43]. In the absence of Shh, Smo activity is repressed 
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by Ptch1; whereas in its presence, Ptch1 undergoes certain conformational changes and 
can no longer suppress Smo, leading to the activation of its downstream molecules such 
as Gli family of transcription factors GLI1, GLI2, and GLI3 (named after glioblastoma) 
(Figure 2) [23, 42, 44].  
 
                 
Figure 2. Schematic representation of the SHH signaling pathway in normal cerebellum 
development. SHH ligand binds to its receptor activating Smo which then activates the 
downstream molecules. The importance of SHH pathway has been demonstrated in 
embryogenesis; however, alterations in this pathway have the potential to induce MB 
formation in cerebellum.  
Genetic study has demonstrated that mutations in the key regulatory molecules of Shh 
pathway induce MB formation [45, 46]. Ptch, a tumor suppressor gene located on 
chromosome 9q22.3, is mutated in an autosomal dominant disorder called Gorlin’s 
syndrome whose characteristic feature is abnormalities in various developmental 
processes with a predisposition to numerous diseases such as MB [47]. Mutations in 
molecules such as PTCH, Suppressor of fused homolog (SUFU), and SMO were 
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identified in more than 25% of sporadic MB, especially in desmoplastic MBs [45, 46]. 
An elevated expression of BMI1, target gene of SHH signaling pathway has been 
observed in MB tumors that deregulate both Rb and p53 pathways leading to the 
development of MB [48]. . Also the requirement of BMI1 for Hedgehog pathway-driven 
MB expansion has been demonstrated [48-51]. A significant growth reduction in mice 
model [Ptch1(+/-)p53(-/-)] of MB, post treatment with SHH pathway inhibitors 
demonstrated the importance of SHH pathway in MB [52]. A conclusive proof for the 
role of SHH pathway in MB induction came from studying the Ptch1 knockout mice 
models [53, 54]. 
1.1.3.2. Wnt signaling 
 
Involvement of WNT signaling has been elucidated in numerous developmental 
processes like CNS progenitor growth, cell expansion, differentiation, and tissue 
homeostasis [55-58].Canonical pathway is activated by the interaction of Wnt with a 
heterodimeric receptor complex – seven-pass transmembrane receptor Frizzled (FZD) 
and co-receptor LRP5/LRP6. The interaction leads to the accumulation of β-catenin and 
consequently activating its downstream signaling cascade [49, 59, 60].. In the absence of 
WNT protein, β-catenin, a key molecule in this pathway, gets phosphorylated at the 
amino terminal region by Axin complex made up of APC (adenomatous polyposis coli 
gene product), CK1 (casein kinase 1) and GSK3 (glycogen synthase kinase 3) leading to 
its ubiquitination and proteosomal degradation [61-63]. However, in the presence of 
WNT ligand, a receptor (FZD-LRP5/LRP6)-ligand interaction occurs, phosphorylating 
Dishevelled (DVL) leading to the interaction of DVL with FZD and releasing β-catenin 
[64, 65]. The stable β-catenin then travels to the nucleus interacting with T-cell 
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factor/lymphoid-enhancer factor (TCF/LEF) transcription factors transcribing 
downstream molecules such as cyclin D1 and c-Myc (Figure 3) [66-69].                      
 
                       
Figure 3. Schematic representation of the WNT signal pathway in normal cerebellum 
development. Interaction of Wnt ligand with its receptor FZD-LRP5/LRP6 complex 
results in the phosphorylation of DVL which then release β-catenin.  
Mutations in certain specific genes involved in WNT pathway have been identified to 
induce MB. APC, an important gene in this pathway, has germline mutations in patients 
with Turcot’s syndrome, those that have a predisposition to give rise to various cancer 
forms along with MB [70, 71]. Inactivated APC leads to the accumulation of β-catenin, 
which consequently elevates the expression of genes involved in the induction of cell 
proliferation and apoptosis [71, 72]. However, the most common mutation in WNT 
signaling of MB (~15%) has been associated with the CTNNB1 gene encoding for the β-
catenin protein molecule, is correlated with a good prognosis [70, 73-76]. To further 
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study the importance of this pathway in MB, various in vivo experiments were 
performed. Transgenic mice with overexpressed stable β-catenin and in the 
presence/absence of p53, demonstrated no formation of MB tumors, indicating that WNT 
signaling by itself is incapable of tumorigenesis [77, 78].  
1.1.3.3. Notch signaling 
 
Notch signaling plays a vital role in critical developmental processes like embryonic 
and postnatal cell fate specification events and maintaining homeostasis in stem and 
progenitor cells during embryogenesis [79-81]. This pathway has mainly four receptors – 
Notch1, Notch2, Notch 3, and Notch 4 and numerous ligands such as Jagged1, Jagged2 
(homologues of serrate), delta-like ligands such as DLL1, DLL3 and DLL4, DNA-
binding protein Cbf1 and effector molecules such as Hes1 and Hes5 [5, 80, 82, 83]. The 
Notch receptor is a single-pass transmembrane protein consisting of a short extracellular, 
a single-pass transmembrane domain and a small intercellular domain. The extracellular 
domain has 36 EGF-like repeats, of which 11
th
 and 12
th
 are capable of forming 
interactions with Delta ligand [84-86]. The Notch intercellular domain (NICD) is made 
up of a high affinity RAM region and a low affinity ANK region (seven ankyrin repeats) 
both necessary for CSL (CBF1/RBPj/Su(H)/Laf-1) transcription factor activation, a long 
nuclear localization sequence that links RAM and ANK, followed by a transactivation 
domain and a C terminus consisting of conserved amino acid proline/glutamic 
acid/serine/threonine-rich motifs known as PEST sequence [87, 88]. 
Notch signaling is activated when either Delta or Jagged protein binds to a Notch 
receptor on the other cell [5]. This interaction results in 2 proteolytic cleavages – First, 
ADAM-17 (ADAM: a disintegrin and a metalloproteinase) cleaves the transmembrane 
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region that sheds the ectodomain region of the Notch receptor leaving behind a 
membrane-tethered intermediate named as NEXT (Notch extracellular truncation) [89, 
90]. -secretase then cleaves NEXT that acts as a substrate, to release the soluble NICD 
in to the cytosol [88, 91, 92]. The NICD then translocate to the nucleus where it binds to 
CSL via the RAM domain displacing HDAC (histone deacetylase) co-repressor and 
activating a co-activator complex (MAML1, SKIP, and histone acetyltransferase). This 
process leads to the elevated transcription of Notch signaling downstream molecules like 
HES1 and HES5 (Figure 4) [79, 93-96].  
Expression of Notch1 in precursor cells of a developing brain and a significant 
expression of Notch2 in the actively multiplying GNPs in EGL have been definite 
indications to suggest the role of Notch signaling in MB [97-100]. Evidence for the 
significance of Notch signaling in MB came from experiments inhibiting various Notch 
pathway key regulators, where a reduction in cell proliferation and an increase in cell 
apoptosis were observed [97, 101, 102]. A poor survival rate in MB patients has been 
linked to high expression of HES1 protein [101, 103]. All these studies have 
demonstrated that targeting Notch signaling can be beneficial towards the treatment of 
MB. 
1.1.3.4. Other signaling pathways 
 
Recent studies have identified various other signaling pathways that might have a 
crucial role in MB tumorigenesis. PI3K/Akt and TGFβ/BMP (bone morphogenetic 
protein) signaling are two other pathways that regulate important cellular functions such 
as cell proliferation, differentiation, survival, angiogenesis, and tumor growth [36, 104-
110]. It has been demonstrated that PI3K/Akt signaling regulates MB cancer stem cell 
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survival post irradiation In vivo [111, 112]. A study has indicated that BMP production in 
the TGFβ signaling induce apoptosis in MB cells [113]. Reports also revealed that BMP2 
inhibits proliferation of GNP cells, presumed cells of MB origin, induced by SHH 
pathway [114].  
                                     
Figure 4. Schematic representation of Notch signal pathway in normal cerebellum 
development. The Notch signal pathway is activated when Jagged or Delta binds to a 
Notch receptor, where the ADAM and the secretase cleave the membrane protein to 
release NICD in to the cytosol [100].  
In the last decade, another important receptor molecule and its signaling pathway 
have been shown the potential to be a therapeutic target for the treatment of MB – 
Platelet-Derived Growth Factor Receptor (PDGFR) (Figure 5). Reports have 
demonstrated that PDGFR α/β are highly expressed in MB and that when subjected to 
inhibition have resulted in tumor reduction [115-118]. However, extensive studies are yet 
to be performed to identify which PDGFR isoform, among α or β or both play a crucial 
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role in MB progression. MacDonald in 2001 identified PDGFRα to be highly expressed 
in MB by gene expression analysis; however in 2003 Gilbertson put down this notion and 
reported that it was PDGFRβ that was vital in MB metastasis [117, 118]. Thus, extensive 
study of these signaling pathways and the molecules involved can be beneficial in 
providing novel approaches in MB treatment.  
                                                                   
Figure 5. PDGFR signaling pathway. The binding of PDGF ligands to PDGFRs leads to 
the activation of PDGFR pathway and its downstream molecules such as PI3K, Ras, 
MAPK. Targeting an alternative pathway as a therapeutic strategy might be a potential 
strategy in the treatment of MB.  
 
1.1.4. MB histological classification 
MB is one of the most common malignancies of childhood brain tumor derived from 
the aberrations arising in the small embryonal neuroepithelial cells of the cerebellum [14, 
119, 120].  Initial classification of CNS tumors distinguished MB from other tumors as 
they had the ability to differentiate along neuronal and glial lines [14, 15]. Another 
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closely related CNS tumors are the Primitive Neuroectodermal Tumors  (PNETs) [121]. 
While MB is a tumor of the posterior fossa or the cerebellum,  PNETs arise in the 
supratentorial regions [122]. Although both PNET and MB have common characteristics 
such as tendency to disseminate via cerebrospinal fluids or clinical attributes such as age 
at presentation, they differ largely based on pathological diversity, morphological 
features and biological behaviors demonstrated in MB and its variants along with the lack 
of PNETs to differentiate via glial and neuronal lines [14, 119, 123-126]. Further studies 
performed on the genetic nature of MB versus PNET have distinctly shown frequent 
chromosome 17 aberrations in MB unlike in PNET [119, 127]. Based on all the 
histological studies World Health Organization (WHO) in 2007 classified MB into four 
variants – classic, desmoplastic, anaplastic or large-cell and nodular [3]. 
1.1.4.1. Classic MB 
 
Classic variant of MB is made up of undifferentiated, small, round or ellipsoidal, blue 
cells with very little cytoplasm and largely composed of dense hyperchromatic nuclei 
[119, 128]. 40% of classic MB exhibit neuroblastic differentiation which appears as 
Homer-Wright rosettes [10, 14]. Staining of these cells with Ki-67 antibody demonstrated 
mitotic cell divisions in 80% of tumors [129]. Hence, mitotic percentage index have been 
used as prognostic indicators for calculating survivability in pediatric MB [130]. Invasion 
of tumor cells have been seen in the cortex, white matter, nuclei of the cerebellum and 
also in the subarachnoid space. Classic MB makes up approximately 64-78% of MBs 
whose mean age of onset is 9 years [14, 131].  
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1.1.4.2. Desmoplastic MB 
 
Tumors classified on the basis of pathological factors describe desmoplasia as a large 
mass of collagenous tissue present within a neoplasm [132]. A biphasic architecture 
consisting desmoplastic variant of MB is made up of lightly stained reticulin-free 
nodules/islands that are surrounded by compactly packed, reticulin-rich, actively 
proliferating, and mitotically active areas [131, 133].  Reticulin staining clearly shows 
nodules or linear trabaculae being separated by collagen [132]. The incidence of 
desmoplastic MB is up to 50% in adults when compared to 15% in children and whose 
onset mean age is 17 years [128, 132].  
1.1.4.3. Anaplastic/large cell MB 
 
Tumor cells belonging to large cell/anaplastic (LCA) variant of MB have ample 
cytoplasm with prominent and pleomorphic nuclei, cell-cell wrapping and extensive 
mitotic activity [134, 135]. It is the most malignant and aggressive form of MB that can 
be easily distinguished from other MBs on the basis of its histological and cytological 
features in H&E stained sections [136]. Anaplastic/large cell MB, with a poor prognosis, 
occurs rarely and they comprise about 4 – 15% of all MBs [10, 14].  
1.1.4.4. Nodular MB 
 
This variant of MB is also referred to as MB with extensive nodularity (MBEN) and 
is very similar to desmoplastic MB. The two differ in their reticulin-free zones where 
these regions become extensively large and abundant in neurophil-like tissue in nodular 
MB [14, 137]. These enlarged nodules consist of neurocytic cells that stream across 
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neurofibrillary matrix. It occurs in children less than 3 years of age and the incidence of 
nodular MB is around 3% but with good prognosis [14].   
Table 1. MB histological classification. Few similarities and differences between 
classical, desmoplastic, LCA, and MBEN subgroups of MB [10, 14, 119, 128, 131, 132, 
137-139]. 
 Classic Desmoplastic Large cell 
anaplasia 
MBEN 
Percentage of 
incidence 
64-78% 50% in adults, 
15% in children 
4-15% 3% 
Mean age of 
onset 
9 yrs 17 yrs 10 yrs < 3 yrs 
Reticulin Negative Positive Negative Positive 
CSF spread Yes Yes Yes yes 
CTNNB1 
mutation 
Yes Yes Yes yes 
Prognosis Moderate Good Poor Good 
Nuclei Dense 
hyperchromatic  
Dense 
hyperchromatic  
Prominent 
and 
pleomorphic  
Dense 
hyperchromatic 
Aggressiveness Moderate Less More Less 
 
1.1.5. MB subgroups 
 Availability of high-throughput techniques for transcriptomics led to an in-depth 
study of MB that discovered the biological distinction prevailing between two MB 
variants like classic and nodular MB, offering the first indications for the presence of 
subgroups such as SHH MB subgroup [140, 141]. While the above mentioned subgroups 
were classified purely on the basis of histological features, MB transcriptomic studies 
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highlighting differences in genetical, transcriptional, demographical, and clinical 
inferences in MB performed in the last ten years utilizing large sample sizes and various 
statistical methods, the researchers in the MB field have come to consent that MB can be 
majorly divided into four subgroups – WNT, SHH, Group 3/C, and Group 4/D based on 
molecular signatures [142-152]. Evidence also suggests the existence of subtypes within 
the subgroups that are molecularly and clinically distinct as listed in (Table 2) [144, 149, 
153-155].  
 Cho et. al. classification: c1 - MYC, c2, and c4 - neuronal differentiation markers, 
GRM1 and GRM8, c3 - SHH signaling, c6 - WNT, c5 - photoreceptor 
transcriptional programs, and expression of GABRA5 [154]. 
 Kool et. al. classification: A - WNT, B – SHH, C - neuronal differentiation genes, 
D - neuronal differentiation genes and  photoreceptor genes, E - photoreceptor 
genes [144]. 
 Thompson et. al. analyzed subgroups A through E on the basis of mutations in 
specific genes in WNT and SHH signal pathway [149].  
As mentioned in (Table 2), to further characterize and study the MB subgroups in detail, 
researchers have developed subgroup-specific animal models which provide the 
investigators a practical platform to test various ideologies for the treatment of MB.  
Various techniques were adopted to identify these subgroups, of which genomic 
technologies were widely used [144, 147, 170-174]. Complete understanding of the 
biology and complexity of MB becomes necessary to find novel approaches for the 
treatment of MB. In-depth study regarding MB subgroup and their specific biomarkers 
can assist in providing MB patients with group-targeted treatment that might drastically 
enhance the chances of prolonged MB survival. 
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Table 2. MB subgroup classification. Based on the studies performed by several research 
groups, MB subgroups can be classified into four main subgroups, WNT, SHH, 
Group3/C, and Group 4/D on the basis of its prevalence, cellular origin, age, genetics, 
histology, immunohistochemical markers, metastasis, and outcome, and available animal 
model for in-depth study of the subgroups [16, 46, 53, 74-76, 141, 149, 156-169]. 
MB 
classification 
Northcott 
et.al.[147] 
Taylor et. 
al.[145] 
WNT SHH Group 3/C Group 4/D 
Cho et. al.[154] c6 c3 c1 c5 c4 c2 
Kool et. al.[144] A B E C D 
Thompson et. al. 
[149] 
B C’, D E, A A, C 
Prevalence 7-8% 28-32% 26-27% 34-38% 
Cellular origin 
Dorsal 
brainstem 
progenitor 
Cerebellar GNP Cerebellar 
stem cell 
Unknown 
Age 
Child 
Adult 
Infant 
Child 
Adult 
Infant 
Child 
Infant 
Child 
Adult 
Genetics 
CTNBB1 mut 
TP53 mut 
Monosomy 6 
PTCH1 mut 
SMO mut 
SUFU mut 
9q del 
MYCN amp 
MYC amp 
Gain OTX2 
Gain Ch. 1q, 8, 
14, 17, 18 
Loss Ch. X, 
10, 11, 13, 16 
CDK6 amp 
Gain Ch. 7, 
12q, 18 
Loss Ch. X, 8 
Isochrom. 17q 
Histology 
Largely classic 
Rarely LCA 
Desmoplastic 
Classic 
LCA 
MBEN 
Classic 
LCA 
Classic 
LCA 
Immunohisto 
chemical 
markers 
CTNNB1 
CKK1 
FilaminA 
YAP1 
GLI1 
SFRP1 
GAB1 
FilaminA 
YAP1 
NPR3 KCNA1 
KDM6A 
Metastasis Rare Variable Frequent Variable 
Outcome 
Favorable Favorable to 
intermediate 
Poor Intermediate 
Animal model 
Blbp-
Cre:Ctnnb1
lox(e
x3)
;TP53
flx
 
Ptch1
+/-
Tp53
-/-
 c-Myc
+
Tp53
-/-
 Unknown 
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1.1.6. MB metastasis and classification 
Risk stratifications classify MB into majorly two groups based on age, degree of 
surgical resection and Chang’s operative staging system [175] – Standard-risk MB and 
High-risk MB (Table 3). The characteristic features of standard-risk MB are patients 
with age 3 years and older, absence of dissemination in the cerebrospinal fluid (CSF) and 
spinal cord, diagnosis performed post operation showing a residual tumor of less than 1.5 
cm
2
; while high-risk MB comprises of patients with age less than 3 years, presence of 
CSF and spinal cord metastasis, evidence of residual tumor greater than 1.5 cm
2
 post 
operation and of LCA histology [9, 176, 177]. Studies have shown that 5-year survival 
rates of patients with standard-risk MB is ~70% while it is 40% for the patients with 
high-risk MB [178].  
Metastasis is a process in which tumor cells detach from their primary location, 
invade and travel to any other location in the body establishing a secondary tumor. It has 
been demonstrated that metastasis is one of the key features that forms an obstacle and 
resists therapy in MB resulting in poor outcome [118, 179]. Pediatric MB at clinical 
presentation are commonly found disseminated to CSF; and at diagnosis are often present 
with metastasis in the spinal cord or with leptomeningeal, bone, bone marrow, lung,  and 
liver metastasis [179-186]. Currently, disseminated MB patients have been grouped under 
operative staging system with International TNM staging designation by Chang et. al. 
where letter T stands for primary tumor (based on the size and extent of involvement, it 
has been subdivided into T1, T2, T3, T4), N has been omitted in MB staging system, and 
M stands for metastasis (subdivided into M0, M1, M2, M3, M4) (Table 3) [175]. 
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Table 3. Chang’s classification of metastatic MB. Based on Chang’s classification of 
metastasis, MB can be divided into T1-T4 and M0-M4 [175]. 
Classification Characteristic features 
T1 
Tumor <3 cm in diameter; located in midline position in the vermis, 
roof of fourth ventricle and cerebellar hemispheres 
T2 
Tumor >3 cm in diameter; further invading one adjacent structure or 
partially filling the fourth ventricle 
T3 
T3a:Tumor invading two adjacent structures or completely filling the 
fourth ventricle with extension into the aqueduct of Sylvius, foramen 
of Magendie or foramen of Luschka, thus providing marked internal 
hydrocephalus 
T3b:Tumor arising from the floor of the fourth ventricle or brain 
stem and filling the fourth ventricle 
T4 
Tumor further spreading through the aqueduct of Sylvius to involve 
the third ventricle or midbrain or tumor extending to the upper 
cervical cord 
M0 No evidence of gross subarachnoid or hematogenous metastasis 
M1 Microscopic tumor cells found in cerebrospinal fluid 
M2 
Gross nodule seedings demonstrable in the cerebellar, cerebral 
subarachnoid space or in the third or lateral ventricles 
M3 Gross nodule seedings in the spinal subarachnoid space 
M4 Extraneuraxial metastasis 
 
1.1.7. MB therapies 
 Sir William Macewen, in 1879, was the first surgeon to successfully operate a 14-
year old girl with pediatric brain tumor [187]. In 1925, the importance of surgery along 
with radiation in MB was first demonstrated by Cushing and Bailey [9, 15]. Since then 
innumerable modern technologies in the field of surgery, chemotherapy, and radiology 
have greatly influenced brain tumor treatments, especially MB. The common symptoms 
of MB patients at presentation are nausea or vomiting, headaches, ataxia, diplopia, 
nystagmus, papilledema, setting sun sign and lethargy [9, 188]. The initial diagnosis of an 
increasing homogenous mass in the midline posterior fossa is performed by computed 
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tomography (CT) scan, with subsequent verification with magnetic resonance imaging 
(MRI) [9, 10, 181, 189]. 
Surgical resection even today is the initial and standard treatment for MB patients. 
Today, surgery is being performed with highest precision, achieving negligible damage to 
normal brain and avoiding neurological damage [2, 189] and the standard regimen for 
standard-risk MB consisted of surgical resection followed by conventional doses of 
radiotherapy comprising of 54-56 gray (Gy) in total (36 Gy to the craniospinal axis along 
with 18-20 Gy to the posterior fossa) (Table 4) [6, 190-192]. The standard treatment for 
MB involves surgery, radiotherapy at craniospinal axis along with chemotherapy (eg. 
vincristine, cisplatin, carboplatin, etopside and cyclophosphamide in different 
combinations) [191, 193]. This combination treatment has been able to achieve a 
favorable overall 5-year survival rate of 70% for standard-risk MB patients [6, 176, 194]. 
Nevertheless, to further achieve absolute MB survival rates stringent and appropriate MB 
treatments are in dire need. 
A high rate of survival has been demonstrated with MB therapies; however, 
complications or side effects are often observed with surgical procedure, radiotherapy or 
chemotherapy. With surgery, there are high chances of infection, bleeding and 
dysfunction. Also, irradiation to posterior fossa results in a syndrome with characteristic 
symptoms of ataxia, mutism, irritability and truncal hypotonia [191, 195-197]. Another 
major concern with surgery is the residual tumor left behind post-operation that 
frequently supports relapse of the disease [198]. Innumerable side effects have been 
monitored in patients subjected to irradiation such as hair loss, radiation dermatitis, 
hearing, endocrine and growth defects, clumsiness and gonadal dysfunction [191, 199, 
200] . Neurotoxicity, bone marrow aplasia, loss of appetite, hepatotoxicity, pulmonary 
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Table 4. MB treatment regimen. Based on the studies performed by several researchers in 
MB treatment, treatment regimen in childhood MB can be basically divided into three 
groups, standard-risk MB (>3 years), high-risk MB (>3 years) and MB in infants. 
 Investigator Treatment 
Standard-risk 
MB  
(> 3 years) 
Packer et. al. 
[190] 
 
23.4 Gy craniospinal and posterior fossa 
irradiation + chemotherapy (vincristine; 
vincristine, cisplatin, lomustine; cisplatin); 5-year 
survival rate ~85% 
Gajjar et. al.  
[161] 
23.4 Gy craniospinal irradiation, followed by 55.8 
Gy to tumor bed + high dose chemotherapy + 
autologous stem cell rescue; 5-year survival rate 
~85% 
High-risk MB 
(> 3 years) 
Evans et.al. 
[201] 
 
36 Gy craniospinal irradiation with posterior fossa 
boost + chemotherapy (prednisone; cisplatin, 
vincristine, lomustine; vincristine); 5-year survival 
rate ~48% 
Packer et. al. 
[190] 
36 Gy craniospinal and posterior fossa irradiation 
+ chemotherapy (vincristine; vincristine, cisplatin, 
lomustine; cisplatin); 5-year survival rate ~85% 
MB in infants 
and young 
children 
Van Eys et. al. 
[202] 
Chemotherapy (nitrogen mustard, vincristine, 
procarbazine and prednisone); long term survivors 
Head Start I & II 
[203-205] 
Cisplatin, vincristine, etopside, cyclophosphamide 
and methotrexate;  myeloblative chemotherapy; 
autologous stem-cell transplant; 5-year survival 
rate ~79% 
 
toxicity, and many more have been noticed in patients with chemotherapy [191]. 
Additionally, a constant effort has to be done to monitor the patient for MB relapse. In 
most cases MB relapse have been detected within two years of initial treatment. Salvage 
therapy in the form of irradiation can be adopted for young children and infants with 
local relapse treated with just chemotherapy at the time of diagnosis [206, 207]. Effective 
use of high-dose chemotherapy with subsequent stem-cell rescue as salvage therapy have 
also been tried however with no significant results [9, 208, 209].  All these reports 
 22 
 
suggest the need for high surveillance of MB patients or alternative methods to minimize 
or to avoid all the challenges confronted during MB treatment.  
1.2. MB and PDGFR 
 Platelet-Derived Growth Factor Receptors (PDGFRα and PDGFRβ) signaling 
activated by its specific ligands (PDGF-AA, - BB, -CC, -DD, and -AB) have been 
demonstrated to trigger numerous cellular processes such as wound healing, cell 
proliferation, cell migration, survival and growth in both normal cells and various cancer 
forms, including MB [117, 118, 210-213]. Cell proliferation and migration studies 
performed using PDGFR inhibitors such as cambogin, Imatinib and Suntinib have clearly 
identified PDGFR as a potential target for MB treatment [115, 116, 214].  
PDGFR signaling has been linked to MB metastasis; however, the dispute as to which 
of the two PDGFR isoforms, PDGFRα or PDGFRβ, is imperative for MB metastasis, still 
remains unresolved. Earlier, efforts were made to define the roles of individual PDGFR 
in MB metastasis. Gene profiling identified both PDGFRα and PDGFRβ to be highly 
expressed in metastatic MB [118, 140, 215-217]; in vivo MB model system developed to 
further verify the gene profile study also demonstrated similar results [218]. Notably, one 
study specifically demonstrated that PDGFRα was highly expressed in metastatic MBs by 
array analysis and it was further proposed to be a bona fide therapeutic target for 
metastatic MB based on the results obtained using a PDGFRα neutralizing antibody and a 
MAP2K1/2 inhibitor[118]. A concern was raised; however, since the PDGFRα probe set 
used in the microarray analysis was subsequently shown to detect PDGFRβ instead, 
leading to the possibility that PDGFRβ rather than PDGFRα is preferentially expressed in 
metastatic MB [117].  
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Hence, in this study we aim to resolve the unsettled argument and to identify the 
isoform of PDGFR that plays a crucial role in MB metastasis possibly by regulating 
specific downstream molecules and miRNAs. We also aim to provide a novel therapeutic 
approach and molecules for targeted MB therapy.  
1.3. PDGFR 
 PDGFRs were first identified from studies on human fibroblasts that exposed the 
existence of 180 kDa receptor, stimulated by its ligand that resulted in the tyrosine kinase 
activity [219-221]. The precursor receptor protein molecule is initially composed of a 120 
kDa protein core which undergoes rapid glycosylation to form a 160 kDa precursor 
molecule, finally maturing into a 180 kDa cell surface receptor [222-224]. The presence 
of two forms of PDGFRs, PDGFRα and PDGFRβ, was demonstrated by performing the 
cross-competition and the saturation binding studies in between the PDGF ligand 
isoforms showing different affinity towards these receptors [225-227]. Also, studies 
performed indicated that the individual PDGFR subunits, α and β, homo-dimerize or 
hetero-dimerize to form three distinct receptor forms – PDGFRαα, PDGFRββ and 
PDGFRαβ [228, 229]. The binding affinity of the ligand isoforms towards these receptors 
are highly restricted such that PDGF-AA, -BB, -AB bind to PDGFRα having similar 
binding affinities of Kd, 0.1-0.5 nM; while PDGFR-BB, -AB bind to PDGFRβ with 
higher and lower binding affinities of 0.5 nM and 2.5 nM, respectively [211, 226, 228]. It 
has also been identified that the chromosome location for PDGFRα gene is 4q11-q12 and 
for PDGFRβ gene is 5q23-q31 [222, 227, 230]. Both PDGFR and PDGFRβ have been 
shown to play vital roles in the regulation of embryonic development along with various 
other functions such as cell proliferation, survival, and chemotaxis [231, 232].   
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Table 5. Comparison between PDGFRα and PDGFRβ. Table 5 provides similarities and 
differences in between PDGFRα and PDGFRβ based on their structural moiety and 
functional roles, chromosomal location, amino acid arrangement, and ligand-binding 
affinities [227, 232-253]. 
 Alpha Beta 
Gene 6.5 kb 5.7 kb 
Amino acids 1089 1106 
Cysteines 10 10 
ATP binding site Present  Present 
Ig family Present Present 
Ligand binding PDGF-AA, -BB, -AB PDGF-BB, -AB 
Signal peptide 23 aa 32 aa 
Intracellular 
signaling molecules 
Src, PI3K, SHP-2, Crk, PLC-
1 
Src, Shc, Grb2, SHP-2, Grb7, 
PLC-1, Stat5, Nck, PI3K, 
RasGAP 
Chromosome 
location 
4q11-q12 5q23-q31 
Unique 
phosphorylation site 
Tyr 762 (Crk) Tyr 771 (RasGAP) 
Expression in body 
organs 
Lung alveolar septa and 
intestinal villi, dermis layer of 
the skin, interstitial 
mesenchymal cells of testis 
and kidney, lens epithelium, 
astrocytes of retina, palate 
mesenchyme  
Pancreatic stroma cells, 
glomerulus in kidney, stromal 
cells of breast tissue, human 
connective tissue cells, 
arachnoid tissue of brain, 
pericytes and endothelial cells 
in blood vessels 
Function in normal 
cells 
Mitogenicity, chemotaxis, 
embryonic development, 
development of 
oligodendrocyte compartment 
of the brain 
Mitogenicity, chemotaxis, 
embryonic development, 
kidney development, 
development of peripheral 
neuronal system 
Function in 
cancerous cells 
Proliferation, differentiation, 
metastasis 
Metastasis, transformation, 
angiogenesis, proliferation 
 
1.3.1. PDGF ligands 
PDGF ligands were first identified as a component in serum which was later purified 
from human platelets, present as a di-sulphide bonded protein consisting of two 
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homologous polypeptide chains, A and B, that are arranged in various combinations 
(PDGF-AA, BB, AB) and making up a molecular weight of 30 kDa [244, 254-258]. In 
addition to PDGF-A and B, two new ligands were identified in this family, PDGF-C and 
D, which initiated PDGF-PDGFR signal pathway [259-262]. The PDGF ligands (PDGF-
AA, -BB, -CC, -DD, -AB) interact with PDGFRα or PDGFRβ receptor selectively, 
initiating receptor dimerization and finally signal transduction [225, 229, 263-265]. 
PDGF acts as an important mitogen for many mesenchymal cells such as smooth 
muscle cells, fibroblasts and glial cells [266-268]. Various studies have demonstrated the 
importance of PDGF and its receptors as a vital growth factor for the animal 
development. Studies using knockout mouse have demonstrated that the development of 
vasculature cells are assisted by PDGF-B and its receptor while most of the processes 
during embryogenesis development is supported by PDGF-A and its receptors [241, 269-
273]. Alongside the knockout studies, mutation studies were also performed to testify the 
roles of these growth factors by mutating tyrosines residues in the cytoplasmic tail 
regions of the PDGFRs to phenylalanines that resulted in abrogated PDGFR signaling 
functions [241, 274-276].  All the above mentioned mouse studies clearly testify the roles 
of PDGF and its receptors in animal development. Although PDGF signaling and its 
functions play a critical role in growth and development of numerous cells in animals, 
their aberrations or overexpression can lead to drastic consequences. The first indications 
of PDGF involvement in tumorigenesis emerged when studies revealed 92% homology in 
between PDGF-B and v-sis (an oncogene present in simian sarcoma virus) [267, 277-
280]. Clinical studies indicated the association of the aberrations in the expression of 
PDGF and PDGFRs with the induction and progression of diseases in kidneys, lungs and 
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joints and also in atherosclerosis, pulmonary hypertension and organ fibrosis [267, 279, 
281-285]. Studies performed in the last decade have investigated and identified that 
PDGF-PDGFRs play critical roles in tumor processes such as wound healing, 
angiogenesis, migration, invasion, metastasis [234, 286-290]; especially in brain tumors 
such as glioblastoma and MB [117, 118, 210, 291]. Together, these evidence portray 
PDGF-PDGFRs to be a potential therapeutic target in the treatment of numerous tumors, 
more specifically MB for our studies.  
1.3.2. Identification of PDGFRs 
 cDNA cloning studies of PDGF receptors from murine 3T3 cells identified amino 
acid sequences indicating this surface molecule to be a tyrosine kinase protein consisting 
of a split tyrosine kinase domain [222]. A human homologue of this murine PDGF 
receptor was cloned using DNA probes which further assisted in the study of this gene 
[236, 237, 292]. This receptor molecule was composed of 1106 amino acids containing a 
32 amino acid leader sequence and termed as the beta-subunit (now referred to as 
PDGFRβ). The beta-subunit is initially synthesized as a 160 kDa precursor which 
undergoes glycosylation to form a mature PDGFRβ of 180 kDa [224, 293]. Expression of 
beta-subunits in mammalian cells showed a higher binding affinity of these receptors 
towards PDGF-BB when compared to PDGF-AB (low affinity) and -AA (no affinity) 
[227, 236, 237]. These binding studies also confirmed the ideology of the presence of 
multiple PDGF receptors and that cloned PDGF receptor was of the beta-subunit type 
[225, 226].  
 The gene encoding for the other form of human PDGF receptor was cloned using 
stringency hybridization approach where a DNA probe from either the tyrosine kinase 
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domain of v-fms or the PDGF beta-subunit was used for identification [235, 239]. This 
receptor molecule was composed of 1089 amino acids containing a 23 amino acid leader 
sequence and termed as alpha-subunit (now referred to as PDGFRα). The precursor of an 
alpha-subunit is 140 kDa, the maturation of which results in the 170 kDa PDGFRα [293, 
294]. Expression of alpha-subunits in mammalian cells showed a similar high binding 
affinity of these receptors towards all forms of PDGF ligands unlike the beta-subunit 
[227, 235, 239]. 
1.3.3. PDGFR structure and receptor activation 
 PDGFR is a cell surface protein tyrosine kinase receptor. Structurally, both PDGFRα 
and β consists of mainly three regions – extracellular domain consisting of five ligand 
binding immunoglobulin-like motifs, a single-pass transmembrane domain that separates 
the extracellular and the intracellular domain and an intracellular domain made up of a 
split tyrosine kinase domain and a carboxy terminal region with an overall structural 
amino acid homology of ~44% (Figure 6) [220, 227, 295]. The amino acid sequence 
homologies between different regions of the two receptors are ~30% in the extracellular 
domain, ~48% in the transmembrane domain, ~83% in the juxtamembrane region and 
~28% in the C terminal region. A high percentage of homology is found in the kinase 
domain (~87% in kinase domain 1 and ~74% in kinase domain 2) with ~35% homology 
in the kinase insert region [227, 293, 295]. 
The presence of ten highly conserved cysteine residues in the extracellular domain of 
both receptors has been identified which acts as a spacer resulting in five Ig-like motifs 
for ligand binding [220, 227]. A series of experiments such as co-immunoprecipitation of 
PDGF receptors, competition binding of PDGF to PDGFRs and subunit cross linking 
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Figure 6. PDGFR structure. PDGFR can be mainly divided into extracellular domain, 
transmembrane domain and intracellular domain. The extracellular domain consists of 
five Ig-like domains and the intracellular region is made up of split tyrosine kinase 
domains and a C-terminal region [220, 227, 295]. 
were performed that defined the presence of two PDGF receptors, PDGFRα and β, the 
specific binding affinities of PDGF isoforms towards the individual PDGFRs and the  
mechanism of PDGF receptor dimerization that trigger PDGF-PDGFR signal 
transduction [224, 225, 228]. Studies have shown that PDGF ligand dimeric isoforms 
(PDGF-AA, -BB, -CC, -DD, -AB) with two receptor binding epitopes, are capable of 
binding to the extracellular domains of PDGFRs bringing the receptors together forming 
a receptor homodimer or heterodimer (PDGFRαα, PDGFRββ and PDGFRαβ) (Figure 7) 
[264, 296, 297]. Various studies on subunit cross-linking, coimmunoprecipitation of 
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receptor subunits and competition binding affinity studies have led to the model that the 
two isoforms of PDGF receptors homo or heterodimerize on the basis of high affinity 
binding sites present on the PDGF receptors for the ligands that assist the receptors to 
either form PDGFRαα, PDGFRββ or PDGFRαβ forms [227-229]. Mutational analysis 
have demonstrated that the amino acids making up the epitope in each PDGFR, most 
required for ligand binding, that leads to the dimerization of the receptors resides in the 
outermost three Ig-like motifs [244, 298-302]. PDGFRα bind to both PDGF-A and –B 
chains with high affinity whereas PDGFRβ bind to only PDGF-B chain with high affinity 
and PDGF-A with a low affinity; hence PDGF-AA induces the formation of PDGFRαα 
and PDGFRαβ whereas PDGFR-BB induces the formation of all three forms of PDGFR 
combinations [228, 297, 303, 304].  
                    
Figure 7. PDGFR ligand binding. PDGFRα and β can homo or hetero-dimerize to form 
PDGFRα, PDGFRαβ and PDGFRββ receptors. Each dimer specifically binds to ligand 
dimers; PDGFRαα binds to PDGF-AA, -CC, -AB, -BB, PDGFRαβ binds to PDGF-AB 
while PDGFRββ binds to PDGF-BB, -DD [264, 296, 297]. 
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Transmembrane region of the PDGF receptor plays an insignificant role in receptor 
activation or signal transduction; however it plays a major role in anchoring the receptor 
in the plasma membrane linking the extracellular environment with the internal 
molecules of the cell [305]. The juxtamembrane region separates the transmembrane 
from the tyrosine kinase region in the intracellular domain. This region has been 
demonstrated to play a crucial role in initiating PDGFR kinase activation by 
phosphorylating its 579 and 581 tyrosine residues, leading to the trans-phosphorylation of 
857 tyrosine residue in the activation loop, resulting in the conformational change that 
allows the substrates to have an access to them [306].  
The protein tyrosine domains (kinase domain 1 and 2), unlike in other tyrosine kinase 
receptors like EGFR and  insulin receptor, are split in PDGFR and separated from each 
other by ~100  hydrophilic amino acid containing kinase insert [293, 305, 307]. 
Mutation in autophosphorylation site (tyrosine 751 residue) of the kinase insert region 
has demonstrated its importance in the regulation of interactions with certain subsequent 
downstream cellular proteins such as PI3K [308]. The tyrosine kinase domain is a highly 
conserved region among all receptor tyrosine kinases and with ~80% amino acid 
homology in between PDGFR α and β [227, 293, 305]. The kinase domain is made up of 
two lobes, N terminal lobe consisting of a α helix and five β sheets and a C terminal lobe 
which is majorly helical in nature [309]. Both PDGF receptors consist of a conserved 
glycine-rich consensus sequence GlyXGlyXXGlyX(15-20)Lys , termed as the phosphate 
binding loop, located in between the N and C terminal lobes, that functions as a docking 
site for ATP [310-312]. Studies replacing the lysine residue in the consensus sequence of 
the ATP binding site have demonstrated a complete abolishment of the kinase activities 
highlighting the importance of this sequence in PDGF-PDGFR signal transduction [305, 
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313]. For the substrate to be phosphorylated by the tyrosine kinase, utilizing the energy 
obtained from ATP hydrolysis, it has to first have access to the active site located within 
the kinase domain, which is well protected by 20-30 amino acids stretch of activation 
loop. Phosphorylation of the tyrosine residue in the activation loop, tyrosine residue 849 
for PDGFRα and 857 for PDGFRβ, is necessary for tyrosine kinase enzyme activation in 
PDGFR leading to conformational changes that open the activation loop exposing the 
active site to the cytoplasmic substrate molecules like Src homology2 and protein 
tyrosine phosphatase domains (Figure 8) [308, 309, 314]. C terminal region, the last 
portion of the intracellular domain, a highly divergent region among all receptor tyrosine 
kinases, has been found to play a vital role assisting in enzyme activation process [310]. 
Mutation studies have shown that phosphorylation of tyrosine residues 1009, 1021 in the 
C terminal region of PDGFRβ results in the conformational change ofthe activation loop 
exposing the active site to PLC [315-317]. 
1.3.4. Autophosphorylation and signal transduction 
 Dimerization of two PDGFRs brings the receptor tyrosine kinases adjacent to one 
other leading to the autophosphorylation of conserved tyrosine residues in them [318, 
319]. Two different sets of autophosphorylation sites assist in increasing the catalytic 
efficacies of the enzyme kinase triggering PDGF-PDGFR signal transduction[244]. The 
first set of tyrosine residues reside in the activation loop of the kinase domain which 
when phosphorylated enhance kinase activity. Mutation studies have identified it to be 
Tyr 849 in the PDGFRα and Tyr 857 in the PDGFRβ receptor [244, 308, 320]. The 
second set of tyrosine residues (Tyr 579 and Tyr 581 in PDGFRβ) found outside the 
kinase domains, when phosphorylated provide docking sites for downstream cytoplasmic  
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Figure 8. PDGFR activation. PDGF ligand binds to the Ig-like domain in the extracellular 
region of one isoform of the PDGFR, increasing the affinity for a second receptor in the 
vicinity to form a receptor dimer. Receptor dimerization leads to ATP hydrolysis 
resulting in autophosphorylation of the active sites of PDGFRs thereby activating the 
receptor [308, 309, 314]. 
molecules like Src-homology 2 (SH2) domains [321, 322]. A number of molecules 
containing the SH2 domains have been shown to be activated by PDGFRα and PDGFRβ 
tyrosine phosphorylation, such as SHP-2, PI3K, PLC-1, Grb 7, Crk, Src, RasGaP, Stat 5, 
Shc, and Grb 2 [244, 319, 323-329]. However, distinct binding of Crk molecules has 
been demonstrated with PDGFRα alone (Tyr 762) [319, 330]; similarly, RasGap has 
shown binding specificity towards PDGFRβ only (Tyr 771) and not PDGFRα [331-333]  
(Figure 9). Interestingly, unique tyrosine residue phosphorylation was observed in 
hetero-dimeric PDGFRs induced by PDGF-AB that triggered greater mitogenic signaling 
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pathway when compared to homo-dimeric PDGFRs [334-336]. For example, an elevated 
level of phosphorylation was observed in Tyr 754 PDGFRα and Tyr 771 PDGFRβ in the 
hetero-dimeric form than in the homo-dimeric form [336, 337].  
 
 
Figure 9. Phosphorylated tyrosine residues in PDGFRαα and PDGFRββ. Receptor 
activation results in phosphorylation of the specific tyrosine residue, phosphorylating the 
active site and triggering unique signal cascade [244, 319, 323-328]. Certain molecules 
like Crk and RasGAP get activated specifically by PDGFRαα and PDGFRββ, 
respectively [331-333]. 
1.3.5. Role of PDGFR signaling in MB progression 
 The significance of PDGFR signaling in MB was demonstrated by McDonald et al. 
by performing an expression profiling on the MB samples and identifying PDGFRα and 
RAS/MAPK pathway to be therapeutic targets for the MB metastasis [118]. However, it 
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was Gilbertson et al. that indicated that it was PDGFRβ and PDGFRα that was 
overexpressed in MB [117]. Till date the debate remains equivocal, thus encouraging our 
study to investigate and to decipher the right isoform of PDGFR molecule that can be 
treated as a potential therapeutic target MB progression. 
In this study we specifically blocked PDGFRα or PDGFRβ using siRNA, shRNA or 
inhibitors in MB cells, Daoy, D283 and D425 that mostly represent SHH subgroups of 
MB, to identify the potential target molecule for MB. In the process, we deciphered a 
novel PDGFRβ-c-Myc-CD44 pathway along with downstream molecules like miR-1280 
and -1260 and their target molecules JAG2 and CDC25A to play a crucial role in MB 
metastasis and progression. MB patient samples were analyzed that indicted the 
possibility of PDGFRβ and CD44 to be distinct target molecules for MB metastasis. We 
also targeted PDGFRβ and c-Myc and evaluated the rate of cell proliferation and 
migration when co-inhibited. In conclusion, our study reveals that PDGFRβ-c-Myc-
CD44 signal pathway can be a potential therapeutic target in the treatment of metastatic 
MB.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1. Cell lines  
Human MB cell lines, Daoy and D283 were purchased from American Type Culture 
Collection (ATCC) and D425 cells were a gift from Dr. Darell D. Bigner [338]. Daoy and 
D283 cells were maintained in modified Eagle’s medium (MEM) containing 10% fetal 
bovine serum (FBS), along with 2 mM non-essential amino acids and 5 mM sodium 
pyruvate; D425 cells were maintained in improved MEM medium containing 10% FBS 
and cultured in 5% CO2 incubator at 37°C. 
2.2. Reagents 
The following reagents were purchased from various manufacturers: anti-human 
PDGFRα rabbit antibody (Santa Cruz), anti-human PDGFRβ rabbit antibody 
(Epitomics), anti-human PDGFRα mouse neutralizing antibody (R&D Systems), anti-
human PDGFRβ goat neutralizing antibody (R&D Systems) c-Myc rabbit antibody 
(Invitrogen), anti-human CD44 mouse IgG (Cell Signaling), Jagged 2 rabbit antibody 
(Cell Signaling), control siRNA (Invitrogen), PDGFRβ siRNA (Invitrogen), 
pGL4.32[luc2P/NF-κB-RE/Hygro] Vector (Promega), PDGFR inhibitor cambogin (a 
novel PDGFR inhibitor identified in our lab) [214], c-Myc siRNA (Santa Cruz), c-Myc 
inhibitor 10058-F4, (Z,E)-5-(4-Ethylbenzylidine)-2-thioxothiazolidin-4-one 
(Calbiochem), microRNA array (Exiqon), TaqMan microRNA assay kit (Applied 
Biosystems), miR-1280 and miR-1260 inhibitors (Applied Biosystems). The pBabe-puro 
CD44 vector, pBabe-puro control vector, packing vectors pUMVC and pCMV-VSV-G 
were obtained from Addgene, c-Myc expressing plasmid was purchased from Origene. 
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2.3. SiRNA transfections 
 SiRNAs are small non-coding ~22 nucleotide base pairs that were used for our 
transfections to knockdown  specific genes for our study [339]. MB cells (2x10
6
) were 
transfected with specific siRNA along with control (scrambled) siRNA using 
lipofectamine ltx (Invitrogen) in opti-MEM reduced serum medium for 4 h following the 
manufacturer’s instruction. Scrambled siRNA served as the control. The serum starved 
cells were then fed with equal volume of MEM medium and kept in culture for 48 h at 
37°C in a CO2 incubator. After 48 h, cells were harvested for total RNA for PCR and 
protein for Western blotting analysis. List of siRNA used along with their sequences are 
presented in (Table 6). 
Table 6. Gene specific siRNAs. Gene specific siRNAs used for gene knockdown in vitro 
with their sequence and source. 
siRNA    Sequence (5’ – 3’)   Source 
Scrambled ACAUCACGUACGCGGAAUACUUCGA  Invitrogen 
PDGFRα GGAGGAUGAUGAUUCUGCCAUUAUA  Invitrogen 
PDGFRβ UCACGGAAAUAACUGAGAUCACCAU  Invitrogen 
c-Myc   CCCAAGGUAGUUAUCCUUAtt  Santa Cruz 
(siRNA pool)  GGAAACGACGAGAACAGUUtt 
   CCUGAGCAAUCACCUAUGAtt  
CD44   GUAUGACACAUAUUGCUUCUUUU Dharmacon 
JAG2   GCAAGGAAGCUGUGUGUAA  Dharmacon 
 (siRNA pool)  GCGUGUGCCUUAAGGAGUA 
   GAACGGCGCUCGCUGCUAU 
   GGUCGUACUUGCACUCACA 
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2.4. Western blot analysis 
Western blot analysis was performed to confirm level of protein expression either 
post gene knockdown or to identify effect of gene knockdown on the downstream 
molecules. The proteins were extracted using standard 50 mM tris lysis buffer (1 M Tris 
pH 7.4, 5 M NaCl, Triton x-100, Roche complete cocktail inhibitor) and its concentration 
was measured by BCA protein assay (Thermo scientific). 40 µg protein of each sample 
was loaded into each well of a gel and SDS-PAGE was performed using 1X running 
buffer (10 X stock – 30g tris base, 144g glycine, 10g SDS) at 80V for 4% acrylamide gel 
and 120V for 10% acrylamide gel. The proteins were then transferred using a transfer 
buffer (running buffer with 20% methanol) onto 0.45 µM nitrocellulose membrane (Bio-
Rad) by Western blotting using 100V on an ice bath for 2 h. The membrane was initially 
incubated with specific primary antibody overnight at 4°C, washed and then incubated 
with secondary antibody adhered to a HRP-conjugate for 2 h. The results were visualized 
using SuperSignal West Pico chemiluminescence Substrate (Thermo Scientific) by 
exposure on the autoradiographic films (Gene Mase). Rabbit secondary antibody 
(BioRad, catalogue # 170-5046) was used at 1:2000 dilutions and mouse secondary 
antibody (Sigma, catalogue # A9917) at 1:5000 dilutions. Experiments were performed in 
duplicate. List of antibodies used, their sources and working dilutions are presented in 
(Table 7). 
2.5. Cell proliferation assay 
 Cell proliferation assay involves a colorimetric measurement of conversion of a 
tetrazolium dye to an insoluble purple colored compound called formazon. In our study 
this assay was performed to analyze the survivability of cells in different conditions. For  
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Table 7. Primary antibodies. Primary antibodies used with their source, catalogue 
numbers and working dilutions. 
Antibody  Source  Catalogue #  Dilution 
PDGFRα  Santa Cruz  sc-338   1:750 
PDGFR  R & D Systems MAB322  1:500 
(neutralizing antibody) 
PDGFRβ  R & D Systems AF385   1:250 
(neutralizing antibody) 
PDGFRβ  Epitomics  1469-1   1:8000 
c-Myc  Sigma   AV32708  1:2000 
Cell signaling  9402S   1:1000 
CD44  Cell signaling  3578   1:1000 
PKCα  Cell signaling  2056   1:1000 
NFB  Cell signaling  3034S   1:1000 
JAG2  Cell signaling  2205   1:1000 
CDC25A  Cell signaling  3652   1:1000 
β-actin  Sigma   A2228   1:6000 
 
the experiments using siRNAs (control siRNA, PDGFRα siRNA, PDGFRβ siRNA, c-
Myc siRNA, CD44 siRNA, JAG2 siRNA), MB cells (2x10
4
/well) were placed in 70% 
MEM, 30% Opti-MEM with 15 pmol siRNA and 0.25 μl/well of lipofectamine 
(Invitrogen) in 96-well plates. Scrambled siRNA served as the control. For the 
experiments using inhibitors, cells (2x10
4
/well) were plated in 96-well plates overnight. 
Then, cells were treated with the relevant controls (equal amount of solvent) or inhibitors 
(SJ001, 10058-F4, miR-1280 and -1260 inhibitors). After 48 h of treatment, cell 
proliferation rates were determined using MTS assay (Promega) as per the 
manufacturer’s protocol. Experiments were performed in triplicate. The results are 
presented as percentage for cell proliferation. 
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2.6. Lactate dehydrogenase (LDH) assay 
Lactate dehydrogenase assay involves a colorimetric measurement of conversion of 
NAD to NADH by the lactase dehydrogenase enzyme released in the medium to form a 
colored compound. In our study this assay was performed to analyze the cell deaths in 
different conditions. Cells (2x10
4
/well) were placed in DMEM without penicillin and 
streptomycin a day before transfection in 24-well plate. After 48 h of transfection, heat 
inactivated culture media were harvested for assessment of released LDH using an LDH 
based in vitro toxicology assay kit (Sigma). The LDH released in the medium reduced 
NAD to NADH forming a colored tetrazolium dye which was read 
spectrophotometrically at 490 nm. The intensity depicted the amount of cell death in the 
sample Experiments were performed in triplicate. The results are presented as fold 
change for cell death. 
2.7. Cell invasion assay 
 Cell invasion assay involves the invasion of tumor cells across the cell matrix coated 
boyden chamber which is then dyed and absorbance read colorimetrically. This asaay 
was performed in our study to analyze the invasive ability of cells in different conditions. 
2.5 x 10
6 
MB cells were seeded in a medium without antibiotics a day before the 
experiment. Daoy cells were transfected with control siRNA, PDGFRα siRNA, PDGFRβ 
and CD44 siRNA for 48 h. D283 cells were treated with either Control or retroviral 
vector containing CD44 cDNA for 24 h along with Wild Type. After which both Daoy 
and D283 cells were starved in the presence of reduced or serum-free medium (Gibco) 
for additional 24 h. On the day of the experiment, the cell invasion chamber assay that is 
performed using a Boyden chamber (Calbiochem InnoCyte cell invasion assay kit 24-
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well) is placed in the CO2 incubator to bring it to room temperature. Warm PBS is added 
to the upper chamber to rehydrate the basal membrane matrix and incubated for 1 h at 
37°C. During the incubation, the treated Daoy and D283 cells are suspended to attain a 
concentration of 2.5 x 10
4
 cells/ml in the serum-free media. PBS is then carefully 
aspirated from the upper chamber without disturbing the matrix-coated membrane. 500 
µL of cell suspension is then added to the upper chamber. 750 µL of complete media 
along with PDGF-BB (chemo attractant – 50 ng/mL) was added to the bottom chamber. 
This set up was incubated for 24 h at 37°C in the CO2 incubator. After incubation, 500 
µL of cell staining solution (Calcein-AM in cell detachment buffer, 1:100 dilutions) was 
added to the unused wells. The cell suspension medium was carefully aspirated from the 
upper chamber and was placed in the cell staining solution. The cells were dislodged by 
gently tapping the bottom of the upper chamber. The chamber was then incubated for 30 
min at 37°C in the CO2 incubator. The upper chamber was then removed and the assay 
was incubated for an additional half hour. 200 µL of each sample of the dislodged cell 
suspension was then taken in the 96-well plate (black) in duplicates and the fluorescence 
measured spectrophotometrically at an excitation wavelength of 485nm and emission 
wavelength of 520 nm. Experiment was repeated thrice.  
2.8. RT-PCR for tissues 
RT-PCR is a technique employed to analyze the cell mRNA expression levels by 
using the cDNA got from RNA using reverse transcriptase. In our study it was performed 
to evaluate the mRNA levels of PDGFR, PDGFRβ and CD44 in MB tissues. RNA was 
isolated from five MB tissues and also from Daoy and D283 cells by using the TRI 
reagent (Sigma) following the manufacturer’s protocol. The quantity and purity of RNA 
 41 
 
isolated was calibrated with the help of NanoDrop 1000 spectrophotometer (Thermo 
Scientific). 1 µg of total RNA was taken to prepare cDNA with the help of SuperScript 
first-strand synthesis system for RT-PCR (Invitrogen) following the instructions 
mentioned by the manufacturer. RT-PCR reaction mix was set up with the help of SYBR 
GreenER qPCR supeermix (Invitrogen) as given in the (Table 8).  
Table 8. RT-PCR reaction mix for tissue samples. RT-PCR reaction mix with its 
components and volume in 1 sample. 
 Components    Volume in 1 sample (µl) 
SYBR GreenER qPCR supermix   12.5 
Forward primer      1 
Reverse primer     1 
cDNA       2 
Distilled water     8.5 
Total       25 
 
The thermal cycler program used to perform the PCR reaction is tabulated in (Table 
9). The experiment was repeated thrice and the Ct values obtained were analyzed by 
using 2
-Ct methodology [340]. 
Table 9. The thermal cycle protocol for ChIP-PCR. The thermal cycle protocol showing 
the PCR program consisting of temperature, time, number of cycles and the cycle 
description.  
 Temp.  Time  Cycle   Description 
 50°C  2 min  1 Uracil DNA glycosylase (UDG) incubation 
95°C  10 min  1 UDG inactivation and Initial enzyme activation 
 95°C  15 sec  40 Denaturation 
 60°C  1 min   Annealing/extension 
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2.9. Immunohistochemistry 
Immunohistochemistry is a technique to stain and evaluate protein expression levels 
in paraffin embedded tissues by unmasking and exposing the antigens present in the cells 
to our gene specific antibodies. In our study this technique was performed to evaluate the 
protein levels of PDGFR, PDGFRβ and CD44 in MB tissues. MB tissues used in this 
study were collected from the primary cerebellar tumors at the University of Texas 
Southwestern Medical Center. Diagnoses were confirmed by pathologists and the use of 
patient tissue for research was approved by the institutional review board (IRB) of Texas 
Southwestern Medical Center and North Dakota State University. Five-micron sections 
sliced from the fresh frozen tissues were stained for PDGFRα, PDGFRβ and CD44 
protein expression using a colorimetric method as described previously [341, 342]. 
Briefly, slides were fixed in -20°C cold acetone for 2 min, and pre-treated with H2O2 for 
5 min at room temperature.  After blocking the non-specific binding site using a 
phosphate buffer (PBS) containing 2% FBS, the tissue sections were incubated with the 
primary antibodies (anti-human PDGFRα rabbit antibody or anti-human PDGFRβ rabbit 
antibody or anti-human CD44 mouse antibody along with rabbit and mouse IgG as 
control) overnight at 4°C. Following 3 washes with 1xPBS containing 0.3% triton-100, a 
biotinylated anti-mouse IgG/anti-rabbit IgG (H+L) secondary antibody (Vector 
Laboratories) was applied to the tissue sections for 2 h at room temperature. The signal 
was visualized using ABC reagent from the Vector Laboratories by following the 
company’s instruction. Images were captured by using a microscope (Olympus). 
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2.10. Overexpression of CD44 
 Retroviraal infections is a method that involves using the virus particles carrying the 
plasmid for gene expression of a gene of interest to the target cells. In our study CD44 
overexpression was performed on the D283 cells to evaluate the effect of CD44 on MB 
cell invasion. 1x10
6
 HEK 293 cells were seeded in DMEM the previous night to attain 
30% confluency on the day of the experiment. The cells were then co-transfected with 0.9 
µg of pUMVC (gag/pol expression vector), 0.1 µg of VSV-G (expression vector) and 1 
µg of either Babe puro (Control) or Babe CD44 (CD44 cDNA) vector (Addgene) using 
Lipofectamine (Invitrogen) and incubated overnight at 37°C. The medium was replaced 
with fresh medium to dilute out the cytostatic factor. It was further incubated for 48 h and 
72 h after which the supernatants were collected after passing them through a 0.45 µM 
syringe filter. The supernatants were then diluted with the medium and placed on the 
2x10
6
 D283 cells in the presence of polyprene (8 µg/ml). The set up was incubated for 
further 24 h after which either the cells were lysed to extract the proteins for western 
blotting to confirm the expression of CD44 in D283 cells or the cells were taken for 
invasion assay. 
2.11. Wound healing assay 
 Wound healing assay involves the evaluation of the ability of cells to migrate and 
heal the artificially created wound. In our study this assay was performed to evaluate the 
effect of specific genes on MB cell migration. For the experiments using siRNAs, Daoy 
cells were grown up to 80% confluence and then transfected with specific siRNA 
(PDGFRβ siRNA, c-Myc siRNA, JAG2 siRNA) using lipofectamine ltx (Invitrogen) in 
opti-MEM reduced serum medium for 4 h following the manufacturer’s instruction. 
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Scrambled siRNA served as the control. The cells were then fed with equal volume of 
MEM medium and kept in culture at 37°C in a CO2 incubator for 36 h. For the 
experiments using inhibitors, Daoy cells were also treated with specific inhibitors 
(PDGFR inhibitor, c-Myc inhibitor, miR-1280, and -1260 inhibitors). Equal amount of 
solvent served as a control. At the 36 h time point, cells were detached, and equal number 
of cells was re-distributed in a 48 well plate. After 48 h incubation, an artificial wound 
was made using a 100 µl pipette tip by scraping across the bottom of the well. The 
medium was changed to remove all the detached cells. Movement of cells into the wound 
area was captured by taking images at 0 and 24 h using a phase-contrast microscope 
(Olympus). Migration rate in percentage was calculated by comparing the width of the 
wound at 0 and 24 h in each sample. Wound healing assay was not performed on D283 
and D425 cells as they are half adherent/half suspension cells. Experiments were 
performed in triplicate. The results are presented as percentage for wound healing. 
Percentage wound healing was calculated using the formula: 
[
                        (   )                                    (    )
                         (   )                                     (    )
]      
2.12. Creation of PDGFRα and PDGFRβ stable knockdown cell lines 
Stable transfections are performed by transfecting cells with shRNA that incorporates 
with the host DNA to transcribe constitutively. In our study we stable transfected Daoy 
cells with Control (scrambled) shRNA, PDGFRα shRNA and PDGFRβ shRNA 
containing plasmids that were prepared using a pRNAT-CMV3.2/Neo vector from 
GenScript which included ampicillin resistance gene (for bacterial selection) and 
neomycin resistance gene (for mammalian cell line selection). ShRNA design consisted 
of the following parts: BamHI and XhoI restriction sites, sense sequence (specific to 
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either PDGFRα or PDGFRβ along with a scrambled sequence not complimentary to any 
genes acting as a Mock), a hair-pin loop sequence, an anti-sense sequence and a 
termination sequence.  
The vector was initially restriction digested with BamHI (Invitrogen) and XhoI 
(Invitrogen) and the digested mixture was run on a 1.2% agarose gel. Interested band on 
the gel was excised off and DNA was extracted from it using the Qiagen gel extraction 
kit. The extracted DNA was then ligated with the shRNA using T4 DNA ligase 
(BioLabs), transformed into competent E. coli cells (One shot
®
 Top 10 competent cells, 
Invitrogen) and plated on to the agar plate containing ampicillin (45 µg/ml). Plasmids 
were isolated from the bacterial culture using ChargeSwitch
®
- Pro plasmid maxiprep kit 
(Invitrogen) following the company’s instructions. The plasmids were then introduced 
into Daoy cells by lipofectamine ltx (Invitrogen) transfection followed by neomycin 
selection (200 µg/ml). The knockdown of PDGFRα and PDGFRβ was confirmed by 
Western blot analysis.  
2.13. miRNA profiling 
 miRNA profiling is an array performed on samples to analyze the differentially 
regulated miRNAs that are expressed as a heat map where green color represents low 
expression and red color represents high expression of a particular miRNA. In our study 
we used Control cells (harboring a control shRNA vector), PDGFRαKD, PDGFRβKD, c-
Myc
KD
 (using c-Myc specific siRNA), PDGFRβKDand c-MycKD double knockdown cells 
(using PDGFRβKD and c-Myc specific siRNA) and CD44KD cells for miRNA profiling. 
The knockdown of all specific genes was confirmed using Western blotting analysis. 
Total RNA was isolated from control, PDGFRαKD, PDGFRβKD, c-MycKD, PDGFRβKD 
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and c-Myc
KD
 double knockdown cells and CD44
KD
 using the miRCURY
TM
 RNA 
isolation kit (Exiqon) following the manufacturer’s protocol. NanoDrop 1000 
spectrophotometer (Thermo scientific) and agarose gel electrophoresis were used to 
assess the quality of the RNA isolated. The samples were labeled using the miRCURY 
LNA
TM
 microRNA Hi-Power Labeling kit Hy3
TM
/Hy5
TM
 and hybridized on the 
miRCURY LNA
TM
 microRNA Array (6
th
 Gen). Experiments were performed in 
duplicate. The quantified signals were normalized (background corrected) using the 
global Lowess regression algorithm and the analyzed data demonstrated differentially 
regulated miRNAs that are presented in the heat map. 
2.14. miRNA validation  
 miRNA validation by TaqMan PCR using total RNA isolated from transiently 
transfected cells was performed to validate the heat map generated by miRNA profiling. 
In our study MB cells were treated with either PDGFRα, PDGFRβ, c-Myc, PDGFRβ and 
c-Myc, CD44 siRNA using scrambled siRNA as control for 24 h. PDGFRβKD Daoy cells 
were also transfected with increasing concentrations (30 nM, 60 nM, and 90 nM) of miR-
1280 and miR-1260 specific inhibitors along with a negative inhibitor (60 nM) for 24 h. 
Total RNA was isolated using TRI reagent (Sigma) following manufacturer’s protocol 
and NanoDrop 1000 spectrophotometer (Thermo Scientific) was used for RNA 
quantification.  1 µg of total RNA was used to prepare miRNA specific cDNA using 
TaqMan
®
 microRNA reverse transcription kit (Applied Biosystems). In brief, primer pool 
was prepared by adding 10 µl of each miRNA, 5x RT primer and making the volume up 
to 1000 µl using 1X TE buffer. RT reaction mix was made by mixing the following 
components (Table 10). 
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3 µl of total RNA (1 µg) was added to each reaction to make the final volume to 15 
µl. cDNA was prepared using the following parameters in a thermocycler – 30 min at 
16°C, 30 min at  42°C and 5 min at 85°C after which the mixture was held at 4°C. The 
synthesized cDNA was then used to perform qRT-PCR using the following reaction mix 
to validate the regulated miRNAs in MB cells (Table 11). 
Table 10. RT reaction mix for miRNA validation. The RT reaction mix showing the 
components with their volume taken for 1 sample. 
  Components     Volume for 1 sample (µl) 
  RT primer pool     6.0 
  dNTP (100 mM)     0.3   
  Multiscribe reverse transcriptase (50 U/µL)  3.0  
  RNase inhibitor (20 U/µl)    0.19 
  10x RT buffer      1.01 
  Nuclease-free water     1.50 
  Total       12 
Table 11. RT-PCR mix for miRNA validation. The RT-PCR mix showing the 
components and the volume taken for 1 sample. 
  Component     Volume for 1 sample (µl) 
  20X TaqMan® MicroRNA assay    0.5  
  TaqMan Universal PCR master mix, no   5  
AmpErase UNG (Applied Biosystems) 
 
Nuclease-free water     3.5 
  Total       9 
1 µl of cDNA was added to make up the volume to 10 µl. RNU6B was chosen as an 
endogenous control. Experiments were performed in duplicates. PCR was performed 
using the following program shown in (Table 12). Fold change obtained from Ct values 
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(using 2
-Ct methodology) was converted into logarithmic base 2 for statistical analysis 
[340, 343]. miRNAs with P-value <0.05 was considered to be differentially expressed. 
Table 12. The thermal cycle protocol for miRNA validation. The thermal cycle protocol 
showing the PCR program consisting of temperature, time, number of cycles and the 
cycle description.  
 Temp.   Time  Cycle   Description 
 95°C   10 min  1  Initial enzyme activation 
 95°C   15 sec  40  Denaturation 
 60°C   1 min    Annealing/extension 
 
2.15. Chromatin Immuno-Precipitation – Polymerase Chain Reaction (ChIP-PCR)  
         Assay 
 
 ChIP-PCR is a technique to analyze the physical interaction between a protein and a   
DNA by identifying the binding regions on the DNA. In our study Mock (scrambled 
shRNA), PDGFRαKD, and PDGFRβKD (test samples) along with c-Myc positive HeLa 
and NFB positive HEK 293 cells were plated the previous night in a 10 cm cell culture 
plate. The next day cells were induced with PDGF-BB (50 ng/ml) for 30 min and later 
cross-linked with 10 ml of 1% formaldehyde for 30 min at room temperature. The 
reaction was ceased by adding 1 ml of 1.37 M glycine and mixed immediately. The plates 
were then placed on ice and washed thrice with Buffer A (Table 13). Cells were then  
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Table 13. Buffer components for ChIP-PCR. The buffer components for ChIP-PCR along 
with their volume in 50 ml stock solution.  
  Buffer A components  Volume in 50ml stock (ml) 
  1X PBS     50 
  Protein cocktail inhibitor   1 tablet 
Buffer B components   Volume in 50ml stock (ml) 
  25 mM Hepes, pH7.8    1.25 
  50 mM MgCl2     1.5 
  1 M KCl     0.5 
  0.1% Igepal CA-630    0.05 
  50 mM DTT     1 
  Distilled water    45.7 
  Protein cocktail inhibitor   1 tablet 
  Buffer C components  Volume in 50ml stock (ml) 
  1 M Hepes, pH7.9    2.5 
  140 mM NaCl     1.4 
  50 mM EDTA     1 
  20% Triton X-100    2.5 
  10% sodium deoxycholate   0.5 
  20% SDS     0.25 
  Distilled water    41.85 
  Protein cocktail inhibitor   1 tablet 
  Buffer D components  Volume in 50ml stock (ml)  
  50 mM Hepes, pH7.9    2.5     
5 M NaCl     5    
 50 mM EDTA     1    
 20% Triton X-100    2.5    
 10% sodium deoxycholate   0.5  
20% SDS     0.25 
Distilled water    38.25    
 Protein cocktail inhibitor   1 tablet  
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Table 13. Buffer components for ChIP-PCR (continued).  
Buffer E components  Volume in 50ml stock (ml)  
50 mM Hepes, pH7.9    2.5 
250 mM NaCl     2.5 
50 mM EDTA     1 
10% sodium deoxycholate   0.5 
20% SDS     0.25 
20% Triton X-100    2.5 
Distilled water    40.75 
Protein cocktail inhibitor   1 tablet 
  Elution buffer components 
  1 M Tris, pH 8.0    2.5 
  50 mM EDTA     1 
  1% SDS     2.5 
  1 M sodium bicarbonate   2.5 
  Distilled water    41.5 
trypsinized and the detached cells were harvested by centrifugation at 1000 rpm for 5 min 
at 4°C. The pellet (2.5x10
6
 cells) was re-suspended in 500 µl of Buffer B (Table 13) and 
kept on ice for 10 min. The cells were dounced 10-15 times to release the nuclei. The 
released nuclei were then harvested by centrifuging at 2000 rpm for 5 min. The cells were 
re-suspended in 500 µl of Buffer C (Table 13). Sonication was performed (using Branson 
Digital sonifier 
®
) at 30% amplitude for 10 sec each three times, making sure the sample 
was placed on ice at least for 1 min in between each sonication. The samples were then 
centrifuged at 14000 rpm for 15 min at 4°C. The supernatant was collected and pre-
cleaned with Protein-A sepharose
TM
 CL – 4B (GE Healthcare – 50 µl of the slurry (80 
mg in Buffer C) per 500 µl of the lysate) with constant rotation for 1 h in a cold room. 
The samples were centrifuged at 2000 rpm for 5 min and the supernatant now containing 
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the pre-cleaned chromatin was collected. 50 µl aliquot of each sample was saved to serve 
as the Input DNA.  To the rest of the sample 5 µl of primary antibody (c-Myc and NFB 
– Cell signaling, control Rabbit IgG – Santa Cruz) was added and incubated in a cold 
room with constant rotation for overnight. Next day 50 µl of Protein-A sepharose slurry 
was added to each sample and incubated for 2 h with constant rotation in the cold room. 
Then, centrifugation was performed at 10000 rpm for 3 min. The beads were then washed 
twice each time with Buffer C, Buffer D, Buffer E (Table 13) and TE buffer. To the 
beads, 200 µl of Elution buffer (Table 13) was added and incubated at 65°C for 10 min. 
Centrifugation was performed at 14000 rpm for 1 min and the supernatant was collected. 
Beads were eluted again to obtain a total 400 µl of eluate. In parallel, the saved Input 
DNA was thawed and 350 µl of elution buffer was added to bring the total volume up to 
400 µl. 16.5 µl of 5M NaCl was added to each tube and incubated at 65°C overnight for 
reverse-cross-linking. 2 µl of RNAse (Sigma) was added the next day and incubated at 
37°C for 1 h. 4 µl of EDTA (0.5 M) and 2 µl of Proteinase K (Qiagen) was added and 
incubated at 42°C for 2 h. Post-incubation the DNA were extracted with 
chloroform/isoamyalcoholonce by centrifuging at 14000 rpm for 10 min. The aqueous 
phase was collected to which 40 µl of sodium-acetate (3M) and 1 ml of ethanol was 
added, vortexed and was incubated at -20°C overnight for precipitation. The samples 
were centrifuges at 14000 rpm for 30 min the next day and the pellet was washed once 
with 80% EtOH. The immuno-precipitate (IP) and the Input sample pellets were re-
suspended in 50 µl of Tris, pH 8.5. The chromatin precipitates were then taken for qRT-
PCR. The following primers were used for quantitative analysis (Table 14). 
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Table 14. ChIP-PCR gene specific primers. ChIP-PCR primers for IKBα (NFB positive 
control), B23 gene (c-Myc positive control) and test primes for both NFB and c-Myc 
along with their sequence.   
Positive control primers: NFB (IkBα gene promoter) 
 CHIP-NFB-primer - F   5'- GGA CCC CAA ACC AAA ATC G -3' 
 CHIP-NFB primer - R   5'- TCA GGC GCG GGG AAT TTC C -3' 
Positive control primers: c-Myc (B23 gene promoter) 
 CHIP-c-Myc primer - F   5'- GCT ACA TCC GGG ACT CAC C -3' 
 CHIP-c-Myc primer - R   5'- GCT GCC ATC ACA GTA CAT GC -3' 
Test primers 
 CHIP-c-Myc-primer - F   5'- CCC TCC GTC TTA GGT CAC TG -3' 
 CHIP-c-Myc-primer - R   5'- TGC CAC CAA AAC TTG TCC AT -3' 
 CHIP-NFB-primer - F   5'- AGA GAG GTG CCC ATT CAC AC -3' 
 CHIP-NFB-primer - R   5'- TCC AAG TGG AAA GAG GGA GA -3' 
The qRT-PCR was performed using the following program shown in (Table 15).  
Experiment was performed in triplicates. Fold change obtained from Ct values (using 
2
-Ct methodology) was converted into logarithmic base 2 for statistical analysis [340, 
343]. Ct values with P-value <0.05 was considered to be significant. 
Table 15. The thermal cycle protocol for ChIP-PCR. The thermal cycle protocol showing 
the PCR program consisting of temperature, time, number of cycles and the cycle 
description.  
 Temp.  Time  Cycle   Description 
 50°C  2 min  1 Uracil DNA glycosylase (UDG) incubation 
95°C  10 min  1 UDG inactivation and Initial enzyme activation 
 95°C  15 sec  40 Denaturation 
 60°C  1 min   Annealing/extension 
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2.16. Statistical analysis 
Each experiment was repeated at least three times. Data is presented as mean values ± 
standard deviation.  Differences between 2 groups were analyzed using Student’s t- test. 
P < 0.05 was considered statistically significant. 
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CHAPTER 3. TO DETERMINE DIFFERENTIAL ROLES OF PDGFRα AND 
PDGFRβ IN MB 
3.1. Introduction 
MB is one of the most common malignant brain tumors in children with an overall 5-
year survival of just ~60% [5, 344]. Several studies have demonstrated that 
overexpression or over-activation of PDGFRs and c-Myc in the tumor tissues of patients 
with MB is associated with poor prognosis [117, 118, 345]. Inhibition of PDGFR 
signaling by siRNA or inhibitors such as cambogin, Suntinib, and Imatinib, induced cell 
death and limited cell migration/invasion in MB cells [115, 116, 214]. However, the 
specific molecular mechanisms that regulate PDGFRα and PDGFRβ directing them to 
distinct signaling pathways and controling MB development are yet to be fully 
understood. 
The objective of this study was to elucidate distinct roles of PDGFRα and PDGFRβ 
in regulating MB metastasis. We hypothesized that individual PDGF receptors regulate 
specific downstream molecules and miRNAs to induce different functions in MB. To 
delegate specific roles of PDGFRα or β, RNA interference approach was used to 
knockdown PDGFRα or β specifically in MB cells using gene specific siRNAs and then 
subjected for function studies. Changes in expression of downstream proteins in 
PDGFRα or β specific pathway were evaluated by Western blot analysis. miRNA 
profiling was also performed to identify miRNAs differentially regulated by PDGFRs. 
Hence, this study aimed to identify certain molecules and possible miRNA targets which 
are involved in PDGFR signaling modulating MB metastasis that leads to new insight 
into MB therapy.  
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3.2. Results and discussions 
3.2.1. Determining the baseline expression of PDGFRα and PDGFRβ in MB cell 
 To elucidate the role of PDGFRα and PDGFRβ in regulating MB metastasis, we used 
two cell lines, Daoy (metastatic) and D283 (uncertain for metastasis), as in vitro model 
systems for our experiments. Although D283 cells were isolated from a metastatic site, 
expression profiling by MacDonald et al. assigned this cell line as “uncertain” for 
metastasis as it did not consist of predictor genes analyzed for MB metastasis [118]. 
Primarily, we determined the baseline expression of PDGFRα and PDGFRβ in both these 
cell lines by Western blot analysis. Proteins from equal number of cells from both cell 
lines were extracted and their concentration was estimated using the BSA assay (Pierce). 
40 µg of proteins from each cell line were used for the SDS-PAGE.  Immunoblotting 
results showed that metastatic Daoy cells expressed both PDGFRα and PDGFRβ ten-
folds higher than uncertain for metastasis D283 cells when normalized with the 
expression of β-actin (Figure 10). This differential expression of PDGFRs in metastatic 
(Daoy) and uncertain for metastasis (D283) cell lines indicated that PDGFRs might play 
a crucial role in MB metastasis.  
                                    
Figure 10. Baseline expression of PDGFRα and PDGFRβ in MB cells. Proteins extracted 
were analyzed by Western blot analysis and normalized by comparing with the 
expression of β-actin. 
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3.2.2. Knockdown confirmation of PDGFRα and PDGFRβ in MB cells 
 Till date, the individual role of PDGFRα and PDGFRβ in MB is not clearly 
understood. To elucidate this, we used gene specific siRNAs to specifically knockdown 
either PDGFRα or PDGFRβ in both MB cell lines. The transient knockdown was 
confirmed by Western blot analysis as shown in (Figure 11). 
A significant knockdown of PDGFRα in PDGFRα siRNA treated cells and PDGFRβ 
in PDGFRβ siRNA treated cells was observed in both MB cells. However, partial gene 
knockdown was obtained in D283 when compared to Daoy cells. We reason that, as 
D283 are largely suspension cells the rate of transfection in these cells was not very 
efficient. β-actin was used as the loading control.                             
 
Figure 11. Knockdown confirmation of PDGFRα and PDGFRβ in MB cell lines. Proteins 
extracted from PDGFRα and PDGFRβ knockdown cells by using specific siRNAs after 
48 h transfection in both Daoy and D283 were analyzed by Western blot analysis and 
normalized by comparing with the house keeping gene β-actin. 
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3.2.3. Determining the roles of individual PDGFRs on MB cell proliferation 
 Specifically knock down PDGFR in MB cells were then subjected to cell proliferation 
assay to analyze the effect of individual receptors on MB cell proliferation. MTS assay 
demonstrated that PDGFRα and PDGFRβ differentially regulated MB cell proliferation. 
PDGFRα siRNA treated cells demonstrated an increase (~20%) while PDGFRβ siRNA 
treated cells demonstrated a marked decrease (~30%) in MB cell proliferation when 
compared to control cells treated with scrambled siRNA (Figure 12). Even though the 
results do not show drastic effects, they clearly indicated that in the presence of PDGFRβ 
(PDGFRα siRNA treated cells) and in the presence of PDGFRα (PDGFRβ siRNA treated 
cells) MB cells demonstrated completely different functions from each other. This result 
also indicated that individual PDGFRs might trigger different pathway regulating the 
expression of different downstream molecules. 
 
Figure 12. Effect of PDGFRα and PDGFRβ on MB cell proliferation. PDGFRα and 
PDGFRβ specifically knocked down in Daoy and D283 MB cells by siRNAs were 
analyzed for cell proliferation by MTS assay after 48 h transfection and presented as 
percentage cell survivability,**p<0.01, *p<0.05 compared to control group.  
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A significant difference in cell proliferation was observed in both Daoy and D283 
cells as shown in (Figure 12).  
3.2.4. Determining the role of individual PDGFRs on MB cell death 
 To further confirm the above obtained results, specifically knocked down PDGFR 
cells were subjected to cell death assay with the anticipation of obtaining a contrary 
result. The assay provided an estimation of the amount of Lactate Dehydrogenase (LDH) 
released from the dead cells into the heat-inactivated medium from both the MB cell lines 
treated with either PDGFRα or PDGFRβ specific siRNAs. The results, as shown in 
(Figure 13) clearly demonstrated that a significant increase, if not dramatic, in fold 
change of LDH was obtained from PDGFRβ knockdown cells when compared to control 
cells. This was because of higher cell death of MB cells in the absence of PDGFRβ in 
both cell lines. Contrary to this, a significant decrease in fold change in the amount of 
released LDH was obtained in PDGFRα knockdown cells when compared to control cells 
due to the fact that PDGFRβ present in those cells induced MB cell proliferation.  
          
Figure 13. Effect of PDGFRα and PDGFRβ on MB cell death. PDGFRα and PDGFRβ 
specifically knocked down in Daoy and D283 MB cells by siRNAs were analyzed for cell 
proliferation by MTS assay after 48 h transfection and presented as percentage cell 
death,**p<0.01, *p<0.05 compared to control group. 
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This result further reinforced the notion that PDGFRα and PDGFRβ play different 
and contrary roles in MB and demonstrated that PDGFRβ assists cell proliferation while 
PDGFRα has opposite effects on MB cells in vitro.  
3.2.5. Determining the role of individual PDGFRs on MB cell invasion 
PDGFRα and PDGFRβ demonstrated opposite effects on MB cell invasion. To 
further analyze the role of individual receptors on MB cell invasion, we subjected the 
metastatic Daoy cells for invasion assay. Annie P. Moseman in our lab performed the 
following experiment. Two methods were applied to determine the roles of PDGFRα and 
PDGFRβ on MB cell invasion: 1) by blocking PDGFR signaling using PDGFRα or 
PDGFRβ specific neutralizing antibodies against a control antibody; and 2) by knocking 
down PDGFRs using PDGFRα or PDGFRβ specific siRNAs against a control siRNA. 
The treated cells were then used to analyze for cell invasion abilities with the aid of cell 
invasion chamber assay.  
A significant decrease in MB cell invasion was observed in PDGFRβ 
knockdown/blocked metastatic Daoy cells. Both approaches demonstrated that PDGFRα 
knockdown/blockage promoted, whereas PDGFRβ knockdown/blockage inhibited cell 
invasion in Daoy cells (Figure 14). Similar trends induced by individual PDGFRs were 
observed in both the methods adopted. From the above experiments we can conceive that 
PDGFRα and PDGFRβ not only play differential roles in MB cell proliferation and cell 
death but in cell invasion too; PDGFRβ assists cell proliferation and cell invasion, while 
PDGFRα has contradictory effects in MB. 
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Figure 14. Effect of PDGFRα and PDGFRβ on MB cell invasion by A) using anti-human 
PDGFRα mouse neutralizing antibody and anti-human PDGFRβ goat neutralizing 
antibody along with their respective control antibodies B) using PDGFRα/β gene specific 
siRNAs with control siRNA after 48 h transfection. Cell invasion chamber analysis if cell 
invasion in vitro **p<0.01 compared to respective controls. 
 
3.2.6. Determining specific downstream molecules regulated by individual PDGFRs 
          in MB 
 
 Differential roles exhibited by PDGFRα and PDGFRβ in MB gave us the insight that 
these receptors might trigger different signal pathways that regulate specific downstream 
A 
B 
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molecules, consequently performing distinct functions in MB. Western blot analysis on 
certain proteins such as c-Myc, CD44 and PKCα extracted from PDGFRα or PDGFRβ 
siRNA treated cells demonstrated that the expression of these proteins were down-
regulated in PDGFRβ knockdown cells alone, while no change in expression was 
observed in PDGFRα knockdown cells. This data clearly suggested that PDGFRα and 
PDGFRβ could possibly activate diverse pathways in MB.  
Another important observation from this study was that a significant level of CD44 
expression was observed in metastatic Daoy cells, whereas an undetectable level of CD44 
was obtained in uncertain for metastasis D283 cells. This result highlighted the possible 
mechanism that might provide MB cells with invasive abilities for metastasis; which is 
PDGFRβ, not PDGFRα, regulating metastasis via modulating the expression of CD44. 
This data suggested that CD44 along with molecules like c-Myc and PKCα, which are 
regulated by PDGFRβ pathway alone might induce cell invasion causing MB metastasis 
(Figure 15). 
3.2.7. Determining NFB activity regulated by individual PDGFRs in MB 
To further identify if NFB is selectively activated by either PDGFRα or PDGFRβ, 
we performed the NFB luciferase assay. A co-transfection of either PDGFR/β siRNA 
along with a plasmid containing the luciferase reporter gene (Promega) was performed. 
After 48 h transfection, the cells were assayed for NFκB activation using the ONE-Glo™ 
Luciferase Assay System (Promega). The results depicted in (Figure 16) clearly 
demonstrated that PDGFRβ siRNA significantly down-regulated the NFB activity in the 
MB cells co-transfected with NFB luciferase plasmid, while no change was observed in 
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Figure 15. Effect of PDGFRα and PDGFRβ on downstream molecules. Protein extracts 
from PDGFRα and PDGFRβ specific knock down in both Daoy and D283 were analyzed 
for downstream target molecules such as c-Myc, CD44 and PKCα after 48 h transfection 
using β-actin as the internal loading control. 
Figure 16. Effect of PDGFRα and PDGFRβ on NFB activity. Daoy and D283 cells co-
transfected with PDGFRα or PDGFRβ siRNA and NFB response element reporter 
plasmid, pGL4.32 [luc2P/NFB-RE], were monitored for luciferase activity after 48 h 
transfection and presented as percentage luminescence, *p<0.05 when compared to 
control cells. TNFα induced cells were taken as positive control. 
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MB cells treated with PDGFRα siRNA. A significant change in NFκB activity was 
observed in the Daoy cells, while non-significant but definite reduction was observed in 
D283 cells. We reason that the high expression of c-Myc downstream of PDGFRβ masks 
the effect of PDGFRβ knockdown on NFκB activity. TNFα induced MB cells were taken 
as the positive control. This data showed that only PDGFRβ and not PDGFRα regulate 
NFB activity in MB cells. 
From all the above data we can conclude that PDGFRα and PDGFRβ have discrete 
pathways and regulate distinct downstream molecules in MB. PDGFRβ specifically 
regulates the expression of c-Myc, CD44, PKCα, and NFB activity in MB cells 
suggesting that PDGFRβ controls MB cell proliferation and invasion via these molecules. 
Also, further analysis of PDGFRβ-CD44 axis by determining the physical interaction 
between the two molecules, also by studying the role of PKC might provide compelling 
result on limiting MB progression.  
3.2.8. Determining the effect of c-Myc on CD44 expression in MB cells 
 Our result demonstrated that c-Myc regulates CD44 expression in MB. Our 
preliminary results demonstrated a PDGFRβ siRNA specific down regulation of c-Myc. 
To further elucidate the effect of c-Myc on other molecules like CD44 and also to 
identify the position of c-Myc in PDGFRβ-specific pathway in MB, we subjected MB 
cells to different treatments – control siRNA, PDGFRα siRNA, and PDGFRβ siRNA in 
the presence or absence of c-Myc plasmid along with single treatments of c-Myc siRNA 
and c-Myc plasmid. 
As expected, from (Figure 17) we observed a significant down-regulation of c-Myc 
expression in the PDGFRβ knockdown cells. Interestingly with the overexpression of c-
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Myc, we observed a proportional increase in CD44 expression. We also observed that, 
overexpression of c-Myc masked the effects of PDGFRα and PDGFRβ specific siRNAs 
on its target genes, indicating that PDGFRβ and c-Myc regulate each other in MB. 
Hence, in PDGFRβ specific pathway, c-Myc plays the role of an intermediary molecule 
between PDGFRβ and CD44 in MB.  
       
Figure 17. Effect of c-Myc on CD44 expression in MB cells. Proteins analysis from 
control siRNA, PDGFRα siRNA, PDGFRβ siRNA in presence or absence of c-Myc 
plasmid, c-Myc siRNA alone and c-Myc plasmid alone in Daoy cells after 48 h 
transfection by Western blotting. β-actin was taken as the loading control. 
Notably, CD44 expression in c-Myc siRNA singly treated cells when compared to 
PDGFRβ siRNA singly treated cells where a complete abolishment of CD44 expression 
was observed, only a partial down-regulation was obtained indicating that both c-Myc 
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and PDGFRβ regulate CD44 expression in MB. MB cells treated with c-Myc plasmid 
alone served as a positive control.  
3.2.9. Determining the effect of c-Myc on NFB activity in MB cells 
 Our previous result demonstrated that c-Myc expression and NFB activity was 
selectively regulated by PDGFRβ alone in MB cells. To further verify the relationship 
between PDGFRβ, c-Myc and NFB, we either knocked down c-Myc alone or 
overexpressed c-Myc in the presence or absence of PDGFRβ siRNA, co-transfecting it 
with NFB response element reporter plasmid, pGL4.32 [luc2P/NFB-RE], to 
investigate its effect on NFB activity in MB cells. TNFα induced MB cells acted as the 
positive control. 
 As demonstrated earlier, PDGFRβ siRNA down-regulated the NFB activity in MB 
cells. However, with overexpression of c-Myc, we observed that NFB activity in 
PDGFRβ knocked down cells was significantly restored. We also noticed a significant 
down-regulation of NFB activity in the c-Myc siRNA treated cells, indicating that c-
Myc regulates the expression of NFB activity and that it is found upstream of NFB in 
the PDGFRβ pathway in MB cells (Figure 18). Notably, no change in NFB activity 
observed in MB cells treated with c-Myc plasmid alone was also considered to be 
significant because of the overexpressed c-Myc in MB cells. We reason that 
overexpression of c-Myc in the already overexpressed environment becomes redundant 
and hence does not drastically modulate the NFB activity. 
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Figure 18. Effect of c-Myc on NFB activity in MB cells. Luciferase assay was 
performed on Daoy cells co-transfected with control siRNA, c-Myc siRNA, c-Myc 
plasmid, PDGFRβ siRNA in the presence or absence of c-Myc plasmid after 48 h co-
transfection and presented as percentage luminescence, *p<0.05, **p<0.01, when 
compared to control cells. TNFα induced cells were taken as the positive control. 
 
From the above two figures (Figure 16, Figure 17) we can conclude that c-Myc acts 
as a transitional molecule in the PDGFRβ pathway, transmitting signal from PDGFRβ to 
either CD44 or NFB in MB. 
3.2.10. Stable knockdown of PDGFRα and PDGFRβ in Daoy cells 
 Studies performed thus far - cell proliferation, cell death, cell invasion, regulated 
downstream molecules, have all provided us with compelling results suggesting that 
PDGFRα and PDGFRβ have different functional roles in MB. To further decipher the 
mechanism and the molecules in the pathway that destine PDGFRα and PDGFRβ to 
direct MB cells in opposing directions, we designed PDGFRα and PDGFRβ specific 
shRNAs to generate PDGFRαKD and PDGFRβKD Daoy cell lines. Mock cell line 
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consisting of scrambled shRNA non-specific to any genes was used as the control. The 
stable knockdown was confirmed by Western blot analysis. β-actin was used as the 
loading control (Figure 19).  
 
Figure 19. Stable knock down of PDGFRα and PDGFRβ in Daoy cells. Protein analysis 
from Daoy cells transfected with shRNAs specific to PDGFRα and PDGFRβ cells by 
Western blotting using β-actin as the house keeping gene. 
 
3.2.11. Heat map presenting differentially regulated miRNAs 
 Heat map generated using the total RNA extracted from the either Mock, PDGFRαKD 
or PDGFRβKD cells revealed ~30 differentially regulated miRNAs. The samples were 
prepared in duplicates. The conflicting functional roles of PDGFRα and PDGFRβ in MB 
cells indicated the existence of certain molecules, such as miRNAs, in the pathway that 
are differentially expressed which enforce PDGFRα and PDGFRβ signals to perform 
distinctly from each other. This led us to investigate the miRNA profiles of each stable 
knock down Daoy cell lines to further intricately analyze the differences persisting in 
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PDGFRα and PDGFRβ signal pathway in MB cells by generating the heatmap (Figure 
20).  
            
Figure 20. Differentially expressed miRNAs in PDGFRα and PDGFRβ stably knocked 
down Daoy cells. Total RNAs extracted from samples were subjected to miRNA 
profiling using 6th Gen miRNA array from Exiqon. The samples were labeled using the 
miRCURY LNA
TM
 microRNA array. The normalized log ratio values obtained from the 
ImaGene
®/Nexus™ microarray analysis software were used for analysis. The heat map 
diagram generated using the clustering algorithms show the result of a one-way 
hierarchical clustering of miRNAs and samples. Each row represents a miRNA and each 
column represents a sample. The color scale illustrates the relative expression level of 
miRNAs. Green color represents an expression level below the reference channel, and red 
color represents expression higher than the reference. 
Heat map generated, as shown in (Figure 20), clearly exhibits that certain miRNAs, 
such as miR-1280, -1260, -193a-3p, -491-3p, - 720, -4286, are differentially expressed by 
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PDGFRα and PDGFRβ.  Expression pattern demonstrates that most of the miRNAs are 
under-expressed in PDGFRαKD while they are overexpressed in PDGFRβKD when 
compared to Mock profile. 
3.2.12. miRNA validation in MB cells 
Two miRNAs, miR-1280, and -1260, were chosen to represent the miRNA profile 
generated from PDGFRα and PDGFRβ stable knock down Daoy cell lines. Initially, total 
RNA isolated from Daoy and D283 cells transiently transfected with PDGFRα and 
PDGFRβ specific siRNA, using scrambled siRNA as control, were subjected to TaqMan 
qRT-PCR for validation.  Results demonstrated that similar expression patterns of the 
chosen miRNAs were obtained in both transiently transfected Daoy and D283 cell lines 
when compared with heat map profile obtained from stably knocked down Daoy cell 
lines, thus validating the expression patterns obtained from PDGFRαKD and PDGFRβKD 
profiles in MB (Figure 21).  
All these data provided us with definite indications that indeed PDGFRα and 
PDGFRβ trigger disparate pathways in MB via regulating specific downstream molecules 
and miRNAs, assigning themselves with distinct functional roles. However, the exact 
mechanism by which PDGFRβ, and not PDGFRα, aids in MB cell proliferation and 
invasion is still unclear. 
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Figure 21. Validation of differentially expressed miRNAs in PDGFRα and PDGFRβ 
transiently transfected MB cells. The expression analysis of miR-1280 and miR-1260 in 
A) Daoy and B) D283 cells by real-time PCR and presented as fold change, *p<0.05 
when compared to control. 
3.3. Discussion and conclusion 
In this study, we demonstrated that PDGFRβ signaling promotes while PDGFRα 
suppresses MB cell proliferation and migration/invasion via the differential regulation of 
their downstream targets (Figure 12, Figure 13, Figure 14, and Figure 15). Recent 
studies have confirmed that PDGFRβ could play a vital role in MB development in vitro 
[115, 116]; however, the exact role of PDGFRα in MB metastasis remains unclear. In this 
study, we demonstrated that PDGFRα and PDGFRβ have distinct functions in MB cells 
A 
B 
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via differentially regulating their downstream targets and that PDGFRβ, not PDGFRα, 
plays a dominant role in the control of metastasis in MB. These results partially agree 
with previous findings [115, 116]. Furthermore, we present evidence supporting the 
notion that the expression of CD44 is required for PDGFRβ regulating MB metastasis, 
and that the PDGFRβ-CD44 regulatory axis, with participation of c-Myc is required for 
the control of metastasis in MB (Figure 15, Figure 17).  
Structure-function analysis shows that although the two PDGFRs have 70% 
homology in the N termini and 80% in the C termini [295], distinct differences exist in 
their ligand binding domain (31% identical) and in a sub-domain located at the c-terminal 
region (a 27-28% homology). These features presumably allow the two receptors to 
display different ligand affinities and/or to interact with different target protein sets to 
mediate distinct functions in vivo and in vitro [217, 295, 346, 347]. To further elucidate 
the differential functional roles of PDGFRα and PDGFRβ in MB cells, stable knockdown 
cells were generated using PDGFRα and PDGFRβ specific shRNAs using mock, non-
specific to any genes, as the control (Figure 19). miRNA profiling of these cells revealed 
a set of differentially regulated miRNAs (Figure 20). To verify the heat map obtained, 
two miRNAs, miR-1280 and -1260, were chosen randomly and its expression in 
PDGFRα and PDGFRβ transiently knockdown MB cells were analyzed by RT-PCR 
(Figure 21). 
In this study, we have shown that PDGFRα and PDGFRβ play distinct roles in cell 
proliferation, survival, and migration/invasion in MB cells, with PDGFRα limiting and 
PDGFRβ promoting cell proliferation and migration/invasion. The disparate cellular 
outcomes support the importance of the inherent domains and the different interacting 
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protein partners that may be recruited to PDGFRα and PDGFRβ c-termini. Our results 
suggest that interference with PDGFRβ and/or its downstream targets may offer novel 
strategies for metastatic MB therapy. 
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CHAPTER 4. TO DETERMINE THE MECHANISM OF PDGFRβ-CD44 AXIS 
REGULATNG INVASION IN METASTATIC MB 
4.1. Introduction 
 Our study so far has shown that PDGFRβ specifically regulates CD44, unlike 
PDGFRα (Figure 17). Our study also showed that high expression of CD44 expression 
was found only in metastatic Daoy MB while no detectable levels of CD44 were found in 
uncertain for metastasis D283 MB cells [348]. From our preliminary data we hypothesize 
that PDGFRβ-CD44 might provide a potential regulatory axis that modulates MB 
metastasis. CD44 is cell surface adhesive protein that functions as a transmembrane 
receptor molecule for all the components making up the extracellular matrix (ECM) such 
as hyaluronic acid (HA) [349]. It undergoes alternative splicing between exon five and 
ten to give rise to various CD44 variants (CD44v) [350, 351], of which CD44 standard 
(CD44s) is the smallest variant of CD44 (80kDa) that has been shown to be highly 
expressed in MB cells [352, 353]. Earlier studies have demonstrated the importance of 
CD44 in disease metastasis such as breast cancer, prostate cancer and non-Hodgkin’s 
lymphoma [354-357]. CD44 expression patterns in various primary brain tumors and 
brain metastasis have been evaluated [353];  However, till date, no study has been done 
to enumerate the importance of CD44 in MB metastasis. Hence, to evaluate the role of 
PDGFRβ-CD44 axis on MB metastasis, we plan to either knockdown CD44 in metastatic 
MB cells or overexpress CD44 in uncertain for metastasis MB cells and then evaluate 
their invasive abilities by performing cell invasion chamber assay.  
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4.2. Results and discussions 
4.2.1. Baseline expression of CD44 in MB 
 Detectable levels of CD44 were observed only in Daoy and not in D283 cells. Two 
MB cell lines were chosen to determine the role of PDGFRβ-CD44 axis on MB 
metastasis – Daoy (metastatic) and D283 (uncertain for metastasis). Initially, the baseline 
expression of CD44 in both cell lines was analyzed by performing Western blotting. β-
actin was used as the internal control (Figure 22).  
                                           
Figure 22. Baseline expression of CD44 in MB cells. Proteins extracted were analyzed by 
Western blot analysis and normalized by comparing with the expression of β-actin. 
  
4.2.2. Determining the role of CD44 in MB metastasis 
 CD44 plays a crucial role in MB metastasis. Our earlier results demonstrated that 
detectable levels of CD44 were observed only in metastatic Daoy cells and not in 
uncertain for metastasis D283 cells and also that knockdown of PDGFRβ resulted in 
almost complete abolishment of CD44 in MB. To further verify the notion that PDGFRβ-
CD44 axis drives metastasis in MB, we either knocked down PDGFRβ or CD44 in Daoy 
cells using gene specific siRNAs or overexpressed CD44 in D283 cells using cDNA 
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retroviral transfection. Overexpression and knockdown of CD44 was confirmed by 
Western blotting using β-actin as the loading control. These cells were then subjected to 
cell invasion chamber assay for 24 h to investigate the effect of CD44 in MB invasion.  
 We observed that in both PDGFRβ and CD44 knockdown cells, invasion of MB cells 
reduced drastically when compared to control cells treated with control siRNA. Similarly, 
a significant increase in invasive ability was observed in CD44 overexpressed D283 cells 
when compared to Wild type D283 and control retroviral cDNA (Figure 23). These 
results clearly indicated that PDGFRβ via CD44 regulated metastasis in MB.  
 
Figure 23. Effect of CD44 on MB metastasis. Protein analysis of Daoy cells transfected 
with control siRNA, PDGFRβ siRNA and CD44 siRNA along with D283 cells Wild 
type, retro-viral cell transfection with either control cDNA or CD44 cDNA after 48 h 
transfection by Western blotting. These cells were then subjected to cell invasion 
chamber assay in vitro, **p<0.01 when compared to their respective controls.   
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 A complete reduction in invasion of CD44 knockdown Daoy cells or a complete 
attainment of invasive ability in the CD44 overexpressed D283 cells was not observed 
from the results obtained from the invasion assay. This suggests that there might be other 
molecules in this pathway that might also have a role to play in MB progression.  The 
above outcome also demonstrates that PDGFRβ alone lacks the ability to control MB 
metastasis but can do so via regulating CD44 expression.  
4.2.3. PDGFRβ-CD44 axis regulates MB progression via c-Myc 
Our results so far demonstrated that CD44 is a mediating molecular coupler in the 
PDGFRβ signaling pathway that functionally integrates the events elicited by PDGFRβ 
and that both molecules play an active role in regulating invasion activity in MB cells. In 
addition, the observation that exposure to c-Myc siRNA reduced the NF-B activities and 
the expression of CD44 in Daoy cells, while the overexpression of c-Myc restored the 
effect of PDGFRβ siRNA on the NF-B activities and CD44 expression (Figure 16, 
Figure 18) suggesting that an integral link exists between the expression of c-Myc and 
CD44 in MB cells. These data suggest that the expression of c-Myc is required for 
PDGFRβ signaling to activate the NF-B pathway and to control CD44s expression. To 
further determine whether PDGFRβ stimulating CD44 expression requires c-Myc and/or 
NF-B in MB cells, the quantities of c-Myc and NF-B molecules binding to the CD44 
promoter in Daoy cells with or without stable knockdown of either PDGFRα or PDGFRβ 
in response to PDGF-BB stimulation were analyzed using chromatin 
immunoprecipitation (ChIP) coupled with real-time PCR.  
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As shown in (Figure 24), the binding of c-Myc to CD44 promoter in PDGFRβ 
knockdown cells compared to the control or PDGFRα knockdown cells was largely 
reduced, while the binding of NF-B to CD44 promoter had little change in both 
PDGFRαKD and PDGFRβKD conditions. These results demonstrated that PDGFRβ 
enhances the expression of CD44 in MB cells via c-Myc. 
            
Figure 24. PDGFRβ-CD44 axis regulates MB progression via c-Myc, not NFB. The 
specific binding of c-Myc and NFB to the CD44 promoter region in wild type, 
PDGFRαKD and PDGFRβKD Daoy cells determined by ChIP-PCR and presented as fold 
change, *p<0.01 when compared to respective controls. 
 
4.2.4. Determining PDGFR-CD44 mRNA expressions in MB patient samples 
 Our results from the in vitro system clearly demonstrated that PDGFRβ-CD44 axis 
regulates MB metastasis. To further establish the relationship between PDGFR-CD44 
with metastasis, total RNA extracted from five MB tissue samples (M-stage unknown at 
the time of analysis) obtained from the surgically resected primary cerebellar tumors 
from the University of Texas Southwestern Medical Center (one with cervical and lumbar 
metastasis and the rest four without metastasis) and also from Daoy and D283 cell lines 
* 
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were subjected to RT-PCR. Differential levels of PDGFRα, PDGFRβ and CD44 levels 
were evaluated using GAPDH as the internal control by Dr. Fengfei Wang.  
Blinded analysis (without a prior knowledge about the metastatic nature of the tumor 
samples) of the tissue samples showed moderate expression of both PDGFRα and 
PDGFRβ in all five samples; however an elevated expression of CD44 was noticed only 
in one sample which was later known to be from the metastatic tumor (Figure 25). 
Similarly, high expression of CD44 was observed only in metastatic Daoy cells and not 
in uncertain for metastasis D283 cells.  
 
Figure 25. Relative expression levels of PDGFRα, PDGFRβ and CD44 in MB cells lines 
and tissue samples. The results of RT-PCR were summarized from the average Ct values 
of duplicated samples from two MB cell lines, Daoy and D283, and five MB patient 
tissue samples which were normalized using the house keeping gene, GAPDH. 
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These results also indicated that  the expression levels of either PDGFRα or PDGFRβ 
alone is not sufficient to decide metastatic fate of the MB cells, and that PDGFRβ along 
with CD44 expression can infer the cells to probably give rise to metastasis.  
4.2.5. Determining PDGFR-CD44 protein expressions in MB patient samples 
 To further verify our deduction that PDGFRβ regulates MB metastasis by modulating 
the expression of CD44, we analyzed the protein levels of PDGFRα, PDGFRβ and CD44 
(metastatic nature of the tumor samples unknown at the time of analysis) in the five MB 
patient samples by immunohistochemistry by Dr. Fengfei Wang. Colorimetric analysis of 
the stained tissue samples either with PDGFRα, PDGFRβ or CD44 along with rabbit IgG 
as control, replicated the results obtained from the RT-PCR showing moderate expression 
of PDGFRα and PDGFRβ in all the samples, with only high expression of CD44 in one 
sample which was later known to be metastatic (Figure 26).  Although the results 
obtained with a few patients’ tumor samples are very preliminary, as there was just one 
metastatic sample that demonstrated a higher expression of CD44 than the rest of the 
non-metastatic samples, they can be considered as a positive approach for further 
consideration in the treatment of MB metastasis. 
The summary (Table 16) of both mRNA and protein expression in all five MB 
patient tissue samples provides us with rudimentary evidence that reinforces our 
deduction about PDGFRβ imposing its effect on MB metastasis via CD44. 
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Figure 26. Expression levels of PDGFRα, PDGFRβ and CD44 in MB. Results are shown 
in two representative group; patient 1 (metastatic) and patient 5 (non-metastatic). The 
immunohistochemistry staining of each gene was performed twice and the results were 
analyzed by two investigators. 
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Table 16. Expression levels of PDGFRα, PDGFRβ and CD44 in all five MB tissue 
samples. The results of RT-PCR were summarized from the average Ct values of 
duplicated samples from five MB patient tissue samples which were normalized using the 
house keeping gene, GAPDH. When the actual Ct value for a particular gene from a 
sample was ≥ 33, it was considered as low expression (+/-, -). The protein levels after 
immunohistochemistry were scored according to the color and intensity of staining of 
whole tissue.
 
 
 
4.3. Discussions and conclusions 
In this study, we present evidence supporting the novel PDGFRβ-CD44 regulatory 
axis and contribution by transcription factors, i.e. c-Myc and NFB, in the control of 
metastasis in MB. As mentioned, whether or not PDGFRα, β, or both, are required for 
MB metastasis has been contested [117, 118]. However, both metastatic and non-
metastatic MB tissues expressed comparable levels of PDGFRs (PDGFRα compared with 
PDGFRβ) as analyzed by real time RT-PCR (Figure 25). Thus, additional factors drive 
MB metastasis, not merely PDGFRα or β.  A reasonable candidate, CD44, has surfaced 
from our studies; of note, the high expression level of CD44 was detected only in the 
metastatic MB tissue and not in the tissue from the other four patients without metastasis 
(Figure 12). However these results are very preliminary as a higher expression of CD44 
was noticed in only one metastatic sample when compared to the rest non-metastatic 
samples. It is worth noting that to minimize bias, the protein and gene expression data of 
MB tissues were obtained in the absence of information of the metastasis status of the 
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tissues. Equally important, the differential expression of CD44 can be replicated in the 
metastatic and uncertain for metastasis MB cell lines, Daoy and D283 cells, suggesting 
that the latter can serve as a reasonable in vitro model for further investigation of the 
mechanism of metastasis by PDGFR. Furthermore, the metastatic rate of MB cells was 
shown to be modulated by the knockdown of CD44 in the metastatic Daoy cells and 
overexpression of CD44 in the uncertain for metastasis D283 cells. These data provide 
further support that CD44 plays an important role in MB metastasis (Figure 23) and that 
the expression of CD44 is required for PDGFRβ regulating MB metastasis.  Moreover, 
we also found that c-Myc is downstream from PDGFR signaling but upstream of CD44, 
which is in partial agreement with our microarray data from MEFs [217].  
Because our data showed that PDGFRβ is involved in the control of c-Myc and NF-
B, and because NF-B activation has been shown to activate c-Myc promoter in 
fibroblasts in response to PDGF signaling [358], it is likely that PDGFRα and PDGFRβ 
differentially regulate metastatic MB functions via several key downstream targets such 
as PKCα, c-Myc, NF-B activity, and CD44 (Figure 15, Figure 16). A new PDGFRβ-
CD44 regulatory axis in MB cells has been put-forth from our studies. Among these 
targets, c-Myc and CD44 play a critical role in PDGFRs signaling to control MB 
metastasis. Though we firmly confirmed our hypothesis that PDGFRβ-CD44 regulatory 
axis controls metastasis in MB patients (Figure 25, Figure 26), this study is a proof of 
concept (POC) in terms of clinical MB tissues and larger clinical MB specimens may be 
extended. 
In summary, based on our preliminary results, we can clearly show that PDGFRβ, not 
PDGFRα, plays an essential role in MB metastasis, and that the PDGFRβ-CD44 
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regulatory axis might control metastasis in MB patients. Our study suggests that 
PDGFRβ signaling antagonists and/or inhibitors may find efficacy as novel therapeutic 
agents in the treatment of metastatic MB. Our findings that CD44 is a downstream target 
of PDGFRβ signaling and c-Myc is an important molecular mediator suggest that novel 
targets for the control of MB metastasis may lie in the co-targeting of PDGFRβ, c-Myc, 
and CD44. This approach may shift the focus from more commonly employed targets 
such as PI3K/Akt and MAPKs which, because of their global involvement in the 
functions of multiple cell types, may be more likely to produce off-target side effects.  
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CHAPTER 5. EFFECT OF CO-INHIBITING PDGFRβ AND C-MYC IN MB AND 
IDENTIFICATION OF NOVEL MB TARGETS 
5.1. Introduction 
Several studies have shown that over-expression/over-activation of genes such as 
PDGFRs and c-Myc in the tumor tissues of MB patients are correlated to MB patients 
with an extremely aggressive tumor phenotype and poor prognosis [117, 118, 345, 359]. 
Our recent study shows that only an elevated level of PDGFRβ in the patients correlated 
with a poor outcome [360]. Disrupting PDGFR signaling in MB cells using either 
PDGFRβ specific siRNA or PDGFR inhibitor such as cambogin (SJ001), Imatinib and 
Sunitinib have been demonstrated to decrease cell proliferation and migration of MB 
cells [115, 116, 214].  
c-Myc, a proto-oncogene, is a transcription factor controlling multiple cellular events 
such as proliferation, cell cycle progression, apoptosis and differentiation, by regulating 
the expression of its target genes [361-364].  It was found that both genomic 
amplification and/or promoter activation of c-Myc gene are common events in MB cells 
and overexpression of c-Myc promotes tumorigenesis while inhibition of c-Myc induced 
tumor growth in vitro and in vivo [345, 359, 365, 366]. Although previous studies have 
shown both c-Myc and PDGFRβ to be potential therapeutic targets for MB, the effects of 
co-targeting these two molecules and the mechanism by which abnormal PDGFRβ 
signaling and overexpression of c-Myc enhance MB progress is not clear so far. In this 
study we co-inhibited both PDGFRβ and c-Myc using specific siRNAs and inhibitor 
molecules to investigate their effect on cell proliferation and migration. Additionally in 
this study, we performed miRNA profiling on PDGFRβKD, c-MycKD and PDGFRβKDc-
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Myc
KD
 cells along with mock as control to identify differentially regulated miRNAs in 
MB. Here we have integrated miRNA profiling data and a bioinformatics aided target 
prediction tool to identify novel potent targets in MB [367, 368]. 
5.2. Results and discussions 
5.2.1. Confirming double gene knockdown of PDGFRβ and c-Myc in MB cells 
 Our earlier studies clearly demonstrated that in MB cells PDGFRβ regulates cell 
proliferation and invasion via c-Myc and CD44. We also observed a partial down-
regulation and a complete abolishment in the c-Myc and CD44 expression respectively, 
in the PDGFRβ knockdown cells (Figure 15). We next aimed to co-target both PDGFRβ 
and c-Myc, two important genes involved in regulation of MB cellular function, by using 
gene specific siRNAs. Knockdown of genes was confirmed by Western blotting, as 
shown in (Figure 27) with β-actin as the loading control in all three MB cell lines, Daoy, 
D283 and D425. As a proof-of-principle we demonstrated the effects on an additional cell 
line, D425.   
We observed a significant knockdown in PDGFRβ and c-Myc in both single and 
double knockdown cells. Also, as expected only a partial downregulation in c-Myc was 
observed in PDGFRβ knockdown cells. 
5.2.2. Determining the effect of co-inhibition on MB cell proliferation 
Our studies on PDGFR signal transduction revealed that out of the two isoforms, 
PDGFRβ plays a crucial role in MB progression by regulating specific downstream 
molecules such as c-Myc and CD44. All these molecules have been associated with 
cellular functions such as cell proliferation and migration. To further elucidate their roles 
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in MB, we hypothesized that co-inhibiting PDGFRβ and c-Myc can enhance inhibitory 
effects on MB cell proliferation. PDGFRβ and c-Myc were knocked down alone or in 
combination using siRNAs and evaluated for cell proliferation by performing MTS assay.  
 
Figure 27. Double gene knockdown confirmation in MB cells. Protein analysis of 
PDGFRβ and c-Myc in A) Daoy, B) D283 and C) D425 cells extracted from control, 
PDGFRβKD, c-MycKD and PDGFRβKDc-MycKD samples after 48 h transfection by 
Western blotting using β-actin as the loading control. 
A 
B 
C 
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From (Figure 28) we observed that c-Myc plays a greater role than PDGFRβ in MB 
cell proliferation, as evidenced by the results obtained which demonstrated that c-Myc 
knockdown alone inhibited MB cells more than PDGFRβ alone. However when in 
combination, an enhanced additive inhibitory effects on MB cell proliferation was 
observed, ~25% more than c-Myc alone. This indicates that co-targeting PDGFRβ and c-
Myc might provide a better and alternative approach in the treatment of MB.  
 
           
Figure 28. Effect of co-inhibition using siRNAs on MB cell proliferation. MB cells 
transfected with control siRNA, PDGFRβ siRNA, c-Myc siRNA and PDGFRβ+c-Myc 
siRNA were analyzed for cell proliferation after 48 h transfection by MTS assay and 
presented as percentage cell survivability, *p<0.05, **p<0.01 when compared to control. 
5.2.3. Determining IC50 for c-Myc inhibitor on MB cells 
Our results with gene knockdown clearly emphasized the efficacy of co-inhibiting 
two genes, PDGFRβ and c-Myc, in MB (Figure 28). To further analyze the 
pharmacological effects with use of inhibitor molecules, we used 10058-F4 (a previously 
demonstrated effective inhibitor for c-Myc [369, 370]) to first evaluate the IC50 of this 
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drug molecule on MB cells. 10058-F4 was dissolved in DMSO and had a final 
concentration of 0.25% DMSO in cell medium which was non-toxic to cells. MB cells 
were initially treated with increasing concentration of 10058-F4 (0, 12.5, 25, 37.5 and 50 
µM) for 48 h and then subjected to MTS assay to calibrate the IC50.  
We observed a dose-dependent inhibition of MB cell proliferation with gradient 
increase in 10058-F4 c-Myc inhibitor concentration. 50% inhibition of cell proliferation 
was observed at a concentration of 25 µM in all three MB cell lines; indicating that the 
IC50 of the drug molecule on MB cells is 25 µM (Figure 29). 
 
Figure 29. IC50 calibration of 10058-F4 c-Myc inhibitor on MB cells. MB cells treated 
with increasing concentrations of 10058-F4 for 48 h were subjected to MTS assay and the 
results presented as percentage cell survivability, *p<0.05, **p<0.01, ***p<0.001 when 
compared to respective controls. 
5.2.4. Determining the pharmacological effect of co-inhibition on MB cell   
          Proliferation 
 
Our study using siRNAs demonstrated that knocking down both PDGFRβ and c-Myc 
resulted in more than 60% inhibition of cell proliferation (Figure 28). We then aimed at  
verifying the pharmacological effects of co-inhibiting these two genes using PDGFR and 
c-Myc specific inhibitor such as SJ001 (cambogin) and 10058-F4 respectively. SJ001 is a 
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novel PDGFR specific drug whose IC50 is 5 µM in MB cells [214] and 25 µM for c-Myc 
inhibitor 10058-F4 (mentioned above). Although SJ001 has been demonstrated to inhibit 
both PDGFRα and PDGFRβ previously in our lab, we chose SJ001 for our experiments 
as it is a novel PDGFR inhibitor and its effect on MB cell regulation studies were yet to 
be studied [214]. The cells were treated with either SJ001 or 10058-F4 alone or in 
combination to test the pharmacological effects.  
(Figure 30) demonstrated that co-inhibitory effects on MB cells using inhibitor 
molecules specific to PDGFR and c-Myc had greater effects, ~ 75%, than when treated 
alone. The results from both siRNAs and inhibitor molecules indicate that co-targeting of 
molecules to inhibit cell proliferation provides us with a better approach to limit tumor 
progression. 
 
Figure 30. Pharmacological effect of co-inhibition on MB cell proliferation. MB cells 
treated with either SJ001 or 10058-F4 alone or in combination for 48 h were subjected to 
MTS assay and the results presented as percentage cell survivability, *p<0.05, **p<0.01, 
***p<0.001 when compared to respective controls. 
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5.2.5. Determining the effect of co-inhibition on MB cell migration 
Cell migration is an important process in tumor metastasis and progression. Our 
studies on cell proliferation demonstrated that co-inhibition enhanced the inhibitory 
effects on MB cell proliferation (Figure 30). To further evaluate the effect of co-
inhibition on cell migration, Daoy cells were treated with either PDGFRβ or c-Myc 
specific siRNAs and PDGFR and c-Myc specific inhibitors (SJ001 and 10058-F4, 
respectively) alone or in combination and the treated cells were subjected to wound 
healing assay. Images were captured both at 0 h and at 24 h after wound making. Wound 
healing assay was performed only in Daoy cells while cell lines such as D283 and D425, 
being half adherent/half suspension cells, were exempted from the migration study.  
A significant down-regulation was noticed in cells treated with PDGFRβ siRNA and 
SJ001 when compared to c-Myc siRNA and 10058-F4 indicating that while c-Myc 
control MB cell proliferation, PDGFRβ is responsible for MB migration (Figure 
31A&B). However, in the double gene knockdown cells an additive inhibitory effect was 
observed which was stronger (~30%) than c-Myc
KD
 or PDGFRβKD taken alone as shown 
in (Figure 31C). The above results clearly suggest that co-targeting PDGFRβ and c-Myc 
in MB cells can be beneficial in limiting both cell proliferation and migration and with 
further study can also be established as an alternative approach for the treatment of MB. 
5.2.6. Heatmap showing differentially regulated miRNAs by PDGFRβ and c-Myc in           
          MB 
Our study so far has provided us with two important genes, PDGFRβ and c-Myc that 
regulates MB metastasis and progression, and has also proven that co-targeting these 
genes enhances inhibitory effects on MB cell proliferation and migration (Figure 15, 
Figure 30, Figure 31). Our study specializes on the identification of potential therapeutic 
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targets for targeted inhibitory therapy for MB. The search for potential targets led us to 
further elucidate the mechanism by which these molecules control MB progression and to 
dissect their pathway to reveal new molecules regulating vital cellular processes; for this 
we performed miRNA profiling on stably transfected mock, PDGFRβKD (stable 
knockdown) , c-Myc
KD
 (knockdown using gene specific siRNA) and PDGFRβKDc-
Myc
KD
 samples. Specific gene knockdown was initially confirmed by Western blot 
analysis (Figure 32A). As shown in (Figure 32B), heat map generated by Dr. Fengfei 
Wang and Dr. Saeed Salem identified ~30 differentially regulated miRNAs that are 
regulated by both PDGFRβ and c-Myc in common.  
 
Figure 31. Effect of co-inhibition using siRNAs and inhibitors on MB cell migration. 
Wound healing assay performed on Daoy cells treated with A) PDGFRβ and c-Myc 
siRNA alone or in combination, B) PDGFR and c-Myc specific inhibitor alone or in 
combination, C) the results presented as percentage wound closure, *p<0.05, **p<0.01, 
***p<0.001 when compared to respective controls. 
A 
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Figure 31. Effect of co-inhibition using siRNAs and inhibitors on MB cell migration 
(continued). Wound healing assay performed on Daoy cells treated with A) PDGFRβ and 
c-Myc siRNA alone or in combination, B) PDGFR and c-Myc specific inhibitor alone or 
in combination, C) the results presented as percentage wound closure, *p<0.05, 
**p<0.01, ***p<0.001 when compared to respective controls. 
B 
C 
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Figure 32. Differentially regulated miRNAs by PDGFRβ and c-Myc in MB. A) Protein 
analysis of PDGFRβ and c-Myc in PDGFRβKD stable knockdown cells and c-Myc siRNA 
treated cells. B) Heat map generated after data analysis representing the differentially 
regulated miRNAs by mock, PDGFRβKD, c-MycKD and PDGFRβKDc-MycKD cells. Total 
RNAs extracted from samples were subjected to miRNA profiling using 6
th
 Gen miRNA 
array from Exiqon. The samples were labeled using the miRCURY LNA
TM
 microRNA 
array. The normalized log ratio values were used for analysis. Each row represents a 
miRNA and each column represents a sample. The color scale illustrates the relative 
expression level of miRNAs. Green color represents an expression level below the 
reference channel and Red color represents expression higher than the reference. 
A 
B 
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We noticed that a set of miRNAs in PDGFRβKD, c-MycKD , and PDGFRβKDc-MycKD 
samples showed similar trends of regulation when compared to mock cells suggesting 
mainly two things – that both PDGFRβ and c-Myc lie in the same signal pathway and 
that both regulate a particular miRNA in a similar manner in MB. 
5.2.7. miRNA validation in MB cells 
 To further validate the array data obtained by profiling Daoy mock, PDGFRβKD, c-
Myc
KD
 and PDGFRβKDc-MycKD cells, we randomly selected three miRNAs – miR-1280, 
and -1260 and verified their expression regulation in three MB cell lines – Daoy (Figure 
33A), D283 (Figure 33B) and D425 (Figure 33C), by transiently transfecting them with 
gene specific siRNAs. Total RNA extracted from PDGFRβ and c-Myc alone or double 
knockdown cells were subjected to TaqMan RT-PCR to confirm miRNA regulation.  
miR-1280 and -1260 expression levels obtained from three MB cell lines, were in 
accordance with the array data; thus confirming the specific regulation of miRNAs by 
both PDGFRβ and c-Myc. 
5.2.8. miRNA target prediction and validation  
 Our next aim was to identify specific target molecules for the chosen miRNAs. An 
interesting miRNA target prediction database has been made available to the users by 
Wang et. al. that uses wiki interface to predict both conserved and non-conserved 
miRNA targets in animals (http://mirdb.org/miRDB/) [326, 327]. (Table 17) lists the top 
five predicted targets with highest target score for miR-1280 and -1260.  To further 
validate the regulation of the predicted targets, Jagged 2 and CDC25A were chosen as the 
target molecule for miR-1280 and -1260 respectively. Expression patterns of these targets  
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Figure 33. Validation of differentially expressed miRNAs by PDGFRβ and c-Myc in MB 
cells. Total RNA extracted from PDGFRβKD, c-MycKD and PDGFRβKDc-MycKD 
transiently transfected MB cells for 24 h were analyzed for the expression levels of miR-
1280 and -1260 in A) Daoy, B) D283 and C) D425 by TaqMan
®
 microRNA assay from 
Applied Biosystems and presented as fold change, *p<0.05 compared to respective 
controls. 
A 
B 
C 
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molecules in PDGFRβKD, c-MycKD and PDGFRβKDc-MycKD cells were evaluated in three 
MB cell lines, Daoy (Figure 34A), D283 (Figure 34B) and D425 (Figure 34C), by 
Western blotting. 
Table 17. The potential targets of miRNAs in MB cells regulated by PDGFRβ and c-
Myc.  The miRNAs significantly regulated by c-Myc and PDGFRβ in Daoy cells were 
listed in the table and their potential target genes were predicated using a miRNA target 
predication database. 
      
 Protein expression analysis demonstrated that both PDGFRβ and c-Myc single 
knockdown partially down-regulated the expression of Jagged 2 and CDC25; however a 
significant down-regulation in both the target molecules was observed in co-inhibited 
cells when compared to control cells in all three MB cell lines. Thus validating the 
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predicted targets and also indicating that both PDGFRβ and c-Myc simultaneously inhibit 
Jagged 2 and CDC25A to produce a synchronized effect in MB. 
 
 
Figure 34. miRNA target validation. Protein analysis of Jagged 2 and CDC25A in 
PDGFRβKD, c-MycKD and PDGFRβKDc-MycKD transiently transfected MB cells using 
gene specific siRNAs for 48 h in A) Daoy, B) D283 and C) D425 cells by Western 
blotting using β-acting the internal loading control.  
A 
B 
C 
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5.2.9. miRNA - inhibitor testing 
 Our earlier results enumerated that MB cells treated with PDGFRβ siRNA expressed 
higher level of miR-1280 and -1260 when compared to control cells (Figure 32B, Figure 
33). Our results also demonstrated that both PDGFRβ and c-Myc regulate miR-1280 and 
-1260 and Jagged 2 and CDC25A molecules in MB cells (Figure 34). However, the 
miRNA and its target specificity in MB cells still remained unanswered. Hence, we then 
aimed at verifying the miRNA-target specificity by initially transfecting the PDGFRβKD 
stable cells with increasing concentrations (30 nM, 60 nM, 90 nM) of miR-1280 specific 
and miR-1260 specific inhibitors, along with negative inhibitor (60 nM, non-specific to 
all miRNAs) as the control. Inhibitor-miRNA specificity was evaluated by subjecting the 
total RNA extracted from miR-inhibitor transfected cells to TaqMan qRT-PCR. Ct values 
obtained were analyzed according to 2
-Ct
 methodology [340, 343].  
From (Figure 35) we observe a dose-dependent decrease in the expression level of 
miR-1280 and -1260 with the gradient increase in the concentration of miR-inhibitor -
1280 and -1260 respectively. This indicated that the inhibitors used to suppress the 
expression levels of the target miRNAs in MB cells were highly specific and that these 
miR-inhibitors can be used further to evaluate the miRNA-target specificity in MB cells.  
5.2.10. miRNA-target specificity 
 miR-1280 and -1260 specifically target Jagged 2 and CDC25A respectively. In 2010, 
Schopman et al. studies indicated that miR-1280 might be a fragment of the tRNA
Leu
 and 
thus the miRNA should be validated in more detail [371]. As a justification for our 
miRNA studies, we initially validated miR-1280 sequence by using miR-1280 specific 
inhibitors and evaluated its effect on the predicted target molecule, Jagged 2. Hence, to 
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further demonstrate the miRNA and target specificity, miR-inhibitors were chosen for 
specific down-regulation of miR-1280 and miR-1260 to verify if they specifically acted 
upon their target molecules, Jagged 2 and CDC25A respectively, in MB cells. Proteins 
extracted from miR-inhibitor-1280 and -1260 (30 nM, 60 nM, and 90 nM) and negative 
inhibitor (60 nM) transfected PDGFRβKD stable knockdown cells were analyzed for 
change in protein expression of Jagged 2 and CDC25A by Western blotting in MB.  
 
 
Figure 35. miRNA-inhibitor testing. Total RNAs from PDGFRβKD stable knockdown 
cells transfected with miR-1280 and miR-1260 inhibitors (30 nM, 60 nM, 90 nM) for 24 
h were isolated and subjected to TaqMan
®
 microRNA assay from Applied Biosystems 
and presented as fold change, *p<0.05, **p<0.01, ***p<0.001 compared to respective 
controls. 
 
Our results clearly demonstrated a dose-dependent increase in the expression level of 
Jagged 2 and CDC25A with gradient increase in miR-1280 and -1260 inhibitor 
concentration (30 nM, 60 nM, and 90 nM) respectively in both Daoy and D283 cells as 
shown in (Figure 36). β-actin was used as the internal control. From our earlier results 
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we know that PDGFRβKD cells express higher miR-1280 and -1260 when compared to 
control cells (Figure 33). As Jagged and CDC25A are targets of miR-1280 and -1260 
respectively, a down-regulation of their expression was observed in the cells treated with 
negative inhibitor. However, with gradient increase in the inhibitor concentration, dose-
dependent suppression of its specific target molecule was observed.  Thus, verifying the 
specificity of miR-1280 and -1260 to its target molecules Jagged 2 and CDC25A 
respectively. 
 
Figure 36. miRNA-target specificity. Protein analysis of Jagged 2 and CDC25A in 
PDGFRβKD stable knockdown Daoy cells transfected with miR-1280 and miR-1260 
inhibitors (30 nM, 60 nM, 90 nM) for 48 h by Western blotting using β-actin as the 
internal control.  
5.2.11. Role of miR-1280 and -1260 in MB cell proliferations 
 Experiments performed so far have indicated that both PDGFRβ and c-Myc regulate 
the expression of miR-1280 and -1260 in MB (Figure 33). miR-inhibitor experiments 
have also demonstrated that miR-1280 and -1260 regulate the expression of Jagged 2 and 
CDC25A in MB (Figure 34). However, the functional importance of these miRNAs in 
MB is still unclear. To evaluate the role of miR-1280 and -1260 in MB cell proliferation, 
A 
B 
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PDGFRβKD stable knockdown cells transfected with specific miR-inhibitors (60 nM) 
along with a negative inhibitor (60 nM) were subjected to MTS assay.  
When compared to control cells, we observed ~25% to ~15% increase in cell 
proliferation in MB cells treated with miR-1280 and -1260 respectively (Figure 37). 
These results clearly suggest that mir-1280 and -1260 play a definitive role in MB cell 
proliferation. 
 
Figure 37. Role of miR-1280 and -1260 in MB cell proliferation. PDGFRβKD stable 
knockdown Daoy cells treated with either miR-1280 or -1260 inhibitor (60 nM) for 48 h 
were subjected to MTS assay and the results presented as percentage cell survivability, 
*p<0.05 when compared to respective controls. 
 
5.2.12. Role of miR-1280 and -1260 in MB cell migration 
 Both miR-1280 and -1260 induce MB cell migration. Our promising cell proliferation 
results (Figure 37) prompted us to verify the importance of miR-1280 and -1260 in MB 
cell migration. As mentioned above, PDGFRβKD stable knockdown cells were used and 
transfected with either miR-1280 or -1260 (60 nM) along with negative inhibitor as the 
* 
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control (60 nM). The transfected cells were then used to perform the wound healing assay 
to evaluate the functional role of miR-1280 and -1260 in MB progression.  
Our results from (Figure 38A) demonstrated that an increase in cell migratory ability 
was displayed by PDGFRβKD cells transfected with specific inhibitors for either miR-
1280 or miR-1260; inhibition of miR-1280 showed a marked increase in cell migration 
(~55%), while an moderate increase (~15%) was observed in miR-1280 inhibited cells 
(Figure 38B). Cellular functions such as proliferation and migration results (Figure 37, 
Figure 38) clearly enumerated the importance of miR-1280 and miR-1260 in MB. 
 
5.2.13. Role of Jagged 2 in MB cell proliferation 
Our previous results have identified that miR-1280 targets JAG2 in MB (Figure 36). 
Also, we have demonstrated that both PDGFRβ and c-Myc regulate the expression of 
Jagged 2 in MB (Figure 34). To further evaluate the role of Jagged 2 in regulating MB 
cellular functions, we initially knocked down Jagged 2 in three MB cell lines – Daoy, 
D283 and D425, using Jagged 2 specific siRNAs along with control siRNA as control. 
The knockdown was confirmed by Western blot analysis. These cells were then subjected 
to MTS assay to evaluate their role in MB cell proliferation.  
Western blot analysis demonstrated a significant knockdown of Jagged 2 in all three 
MB cell lines transfected with specific siRNA when compared to control siRNA (Figure 
39A). Also, from (Figure 39B) we noticed that in the absence of Jagged 2 a marked 
decrease in MB cell proliferation was observed, ~25% in Daoy, ~20% in D283 and ~23% 
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in D425 compared to control, indicating that Jagged 2 along with mir-1280 and PDGFRβ 
play a crucial role in MB cell proliferation. 
 
           
 
A 
B 
Figure 38. Role of miR-1280 and -1260 in MB cell migration. A)Wound healing assay 
performed on PDGFRβKD stable knockdown Daoy cells treated with miR-1280 and 
miR-1260 inhibitor, B) the results presented as percentage wound closure*p<0.05, 
**p<0.01, when compared to control. 
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Figure 39. Role of Jagged 2 in MB cell proliferation. A) Protein analysis of Jagged 2 in 
MB cell lines after transfection with control siRNA and Jagged 2 specific siRNA for 48 h 
by Western blotting using βactin as the loading control, B) MB cells treated with either 
control or Jagged 2 siRNA for 48 h were subjected to MTS assay and the results 
presented as percentage cell survivability, *p<0.05, **p<0.01when compared to 
respective controls. 
A 
B 
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5.2.14. Role of Jagged 2 in MB cell migration 
 Jagged 2 regulate MB cell migration. Our earlier results have demonstrated that 
Jagged 2 is regulated by both miR-1280 and PDGFRβ pathway in MB (Figure 34, 
Figure 36). We have also seen that Jagged 2 plays a role in regulating MB cell 
proliferation (Figure 39B). To further enumerate its role in MB cell migration, we 
specifically knocked down Jagged 2 in MB and evaluated its effect by performing wound 
healing assay.  
Wound healing assay demonstrated that in the absence of Jagged 2 a significant 
down-regulation (~42%) in MB migration was observed when compared to control cells 
(Figure 40). This result indicated that Jagged 2 regulates MB cell migration along with 
proliferation. Our earlier studies indicated that PDGFRβ regulates MB progression by 
modulating its downstream molecules like c-Myc, and CD44 and certain miRNAs like 
miR-1280 and -1260 (Figure 15, Figure 33). Put together, all the data reinforce our 
notion that PDGFRβ pathway regulates MB metastasis and progression. 
5.3. Discussion and conclusion 
 Published reports, including our own, have shown that inhibition of either PDGFRβ 
or c-Myc decreased cell proliferation and/or migration/invasion [344, 372-375] (Figure 
12, Figure 14). In this study, we determined the effects of co-targeting both c-Myc and 
PDGFRβ using either gene specific siRNAs or inhibitors on MB cell proliferation and 
migration. Additive inhibitory effects on both MB cell proliferation (~60%) and 
migration (~85%) were observed in MB cells knocking down both PDGFRβ and c-Myc 
when compared to single knock down of either PDGFRβ (~25% and ~60%) or c-Myc 
(~40% and 25%).  PDGFRβ siRNA or inhibitor had a greater reduction effect on 
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migration, while c-Myc siRNA or inhibitor largely inhibited MB cell proliferation; 
however, the combined inhibition of both PDGFRβ and c-Myc offers synergistic 
pharmacologic effects in limiting MB progression (Figure 28, Figure 30, Figure 31).  
 
 
 
Figure 40. Role of Jagged 2 in MB cell migration. A)Wound healing assay performed on 
Daoy cells transfected with control or Jagged 2 siRNA for 48 h B) the results presented 
as percentage wound closure, **p<0.01when compared to control. 
 
Recently, non-coding microRNAs have been shown to play crucial roles in cancer 
progression [293, 294]. miRNA profiling on MB tissues from patients has revealed 
A 
B 
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signature patterns to differentiate between childhood and adult MBs, identify their 
molecular subtypes, and also miRNAs which play important roles in MB [301-304]. We 
reasoned that specific miRNAs might be regulated in the PDGFRβ-CD44 regulatory axis 
that controls MB metastasis. To evaluate such miRNAs, we performed miRNA profiling 
to identify differentially regulated miRNAs in MB which might further assist in 
understanding the molecular mechanisms regulating metastatic MB (Figure 32B). 
In this study, by using miRNA profiling, we demonstrated that PDGFRβ and c-Myc 
cells cumulatively regulate MB growth and migration by limiting the expression of a set 
of miRNAs, such as miR- 1260, -1280 and consequently stimulating the expression of 
molecules related to tumor proliferation and metastasis, e.g., CDC25A and Jagged 2 
respectively (Figure 36, Figure 37, Figure 38). To decipher the mechanism that 
synergistically inhibits MB progression by co-targeting PDGFRβ and c-Myc, we 
analyzed the miRNA profiles in wild type, PDGFRβKD, c-MycKD or PDGFRβKDc-MycKD 
Daoy cells, and identified a set of miRNAs that are commonly regulated by both 
PDGFRβ and c-Myc, indicating the existence of a cross-talk prevailing in between the 
two molecules (Figure 32B). With the aid of miRNA predication data base (Table 15), 
several oncogenes and tumor suppressors have been revealed to be potential targets of 
miRNAs regulated by PDGFRβ and c-Myc in the metastatic MB cells. By validating the 
regulated miRNAs and their targets (Figure 33, figure 36), we revealed that PDGFRβ 
and c-Myc regulate the MB cellular events via multiple pathways which include miRNAs 
and their target molecules, such as Jagged 2 that can be a potential target for MB. 
Jagged 2 is a transmembrane glycoprotein that binds to notch receptors regulating cell 
proliferation and differentiation in both normal and pathological conditions [376-381]. 
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Notch signaling plays a vital role in maintaining homeostasis in stem and progenitor cells 
during embryogenesis, aberrations in which can result in MB formation [79, 80]. All 
these studies indicate that targeting Notch signaling can be beneficial towards the 
treatment of MB. CDC25A is modulator protein that controls cell cycle transition from 
G1 to S phase with dual phosphatase activity [382-386]. Several studies have indicated 
that CDC25A is an action molecule that mediates c-Myc signaling for cell proliferation 
[387, 388].  In the siRNA knockdown of either PDGFRβ or c-Myc condition, we 
observed a reverse correlation between the mir-1280 and miR-1260 and their expected 
targets, Jagged 2 and CDC25A, respectively (Figure 36). This result confirmed that 
Jagged 2 and CDC25A are genuine targets of miR-1280 and miR-1260, respectively. 
Notably, either miR-1280 inhibitor or miR-1260 inhibitor had less effect on cell 
proliferation but significantly enhanced cell mobility.  This could be explained by 
reasoning that multiple miRNAs are involved in PDGFR and c-Myc activated signaling 
in MB cells. However, surprisingly, the effects of Jagged 2 siRNA showed similar effects 
as that obtained by miR1280 inhibitor on Daoy cell proliferation and migration. These 
data indicate that Jagged 2 is a potential therapeutic target for MB. 
In conclusion, our results have demonstrated that co-targeting two vital genes limits 
cell proliferation and metastasis. We revealed that PDGFRβ and c-Myc have additive 
effects in promoting MB progression via miRNAs and their targets such as Jagged 2 and 
CDC25A. Our data indicate that blockage of PDGFRβ and c-Myc signaling in MB cells 
simultaneously will co-inhibit cell migration and cell proliferation via modulating a set of 
miRNAs and consequently down-regulating the expression of tumorigenic factors, e.g. 
Jagged 2 and CDC25A and tyrosine kinase receptors, e.g. EGFR, ERBB4. Our results 
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suggest that co-targeting of PDGFRβ and c-Myc provide a novel therapeutic strategy for 
the treatment of metastatic MB and indicate that Jagged 2 is a potential new target of 
MB. 
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CHAPTER 6. DISCUSSION AND CONCLUSIONS, CLINICAL IMPLICATIONS 
AND FUTURE DIRECTIONS 
6.1. Discussions and conclusions 
 In this study, we demonstrated that PDGFRβ but not PDGFRα signaling leads to cell 
proliferation and migration/invasion in MB cells (Figure 12, Figure 14). We present 
evidence supporting the notion that the expression of CD44 is essential for PDGFRβ 
regulating MB migration/invasion, and that the PDGFRβ-CD44 regulatory axis, along 
with the participation of c-Myc, is essential for the metastasis in MB (Figure 17, Figure 
23). We further determined the effects of co-targeting both c-Myc and PDGFRβ using 
either gene specific siRNAs or inhibitors on MB cell proliferation and migration. 
Additive inhibitory effects on both MB cell proliferation (~60%) and migration (~85%) 
were observed in MB cells knocking down both PDGFRβ and c-Myc when compared to 
single knock down of either PDGFRβ (~25% and ~60%) or c-Myc (~40% and 25%) 
(Figure 28, Figure 30, figure 31).  PDGFRβ siRNA or inhibitor had a greater inhibitory 
effect on migration while c-Myc siRNA or inhibitor largely inhibited MB cell 
proliferation; however, the combined inhibition of both PDGFRβ and c-Myc offers 
additive pharmacological effects in limiting MB progression (Figure 28, Figure 30, 
figure 31). To decipher the mechanism that additively inhibits MB progression by co-
targeting PDGFRβ and c-Myc, we analyzed the miRNA profiles in wild type, 
PDGFRβKD, c-MycKD or PDGFRβKDc-MycKD Daoy cells, and identified a set of miRNAs 
that are regulated by both PDGFRβ and c-Myc in common, indicating the existence of a 
cross-talk prevailing in between the two molecules (Figure 32B). With the aid of miRNA 
predication data base (Table 17), several oncogenes and tumor suppressors have been 
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revealed to be potential targets of miRNAs regulated by PDGFRβ and c-Myc in the 
metastatic MB cells. By validating the regulated miRNAs and their targets (Figure 33, 
Figure 36), we revealed that PDGFRβ and c-Myc regulate the MB cellular events via 
multiple pathways which include miRNAs and their target molecules, such as Jagged 2, 
that can be a potent target for MB. 
PDGFRα was reported to be highly expressed in metastatic MBs by array analysis 
and it was further proposed to be a bona fide therapeutic target for metastatic MB based 
on the results obtained using a PDGFRα neutralizing antibody and a MAP2K1/2 inhibitor 
[118]. A concern was raised, however, since the PDGFRα probe set used in the 
microarray analysis was subsequently shown to also detect PDGFRβ, leading to the 
possibility that PDGFRβ rather than PDGFRα is preferentially expressed in metastatic 
MB [117]. Structure-function analysis shows that although the two PDGFRs have 70% 
homology in the N termini and 80% in the C termini of kinase domains [295], distinct 
differences exist in their ligand binding domain (31% identical) and in a sub-domain 
located at the c-terminal region (a 27-28% homology). These features presumably allow 
the two receptors to display different ligand affinities and/or to interact with different 
target protein sets to mediate distinct functions in vivo [295, 346, 347] and in vitro [217]. 
In this study, we have shown that PDGFRα and PDGFRβ play distinct roles in cell 
proliferation, survival, and migration/invasion in MB cells, with PDGFRα limiting and 
PDGFRβ promoting cell proliferation and migration/invasion (Figure 12, Figure 14). 
The disparate cellular outcomes support the importance of the inherent domains and the 
different interacting protein partners that may be recruited by PDGFRα and PDGFRβ c-
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termini. Our results suggest that interference with PDGFRβ or rather its downstream 
targets and regulators may offer novel strategies for metastatic MB therapy. 
We present evidence supporting the novel PDGFRβ-CD44 regulatory axis and 
contribution by transcription factors, i.e. c-Myc and NFB, in the control of metastasis in 
MB (Figure 15, Figure 16). As mentioned before, predicament as to which isoform of 
PDGFRα, β, or both, are required for MB progression is still being contested [117, 118]. 
However, both metastatic and non-metastatic MB tissues expressed comparable levels of 
PDGFRs (PDGFRα compared with PDGFRβ) as analyzed by real-time RT-PCR (Figure 
25). These results indicate that additional factors drive MB progression, not merely 
PDGFRα or β.  A potential candidate, CD44, has surfaced from our studies; of note, the 
high expression level of CD44 was detected only in the metastatic recurrent MB tissue 
and not in the tissue from the other four patients without metastasis (Figure 26). It is 
worth noting that we have ruled out the possible bias as the protein and gene expression 
data of MB tissues were obtained in the absence of information of the metastasis status of 
the tissues. Equally important is that the differential expression of CD44 can be replicated 
in the metastatic and uncertain for metastasis MB cell lines, Daoy and D283 cells, 
suggesting that the latter can serve as a reasonable in vitro model for further investigation 
of the mechanism of metastasis by PDGFR. Furthermore, the metastatic rate of MB cells 
was shown to be modulated by the knockdown of CD44 in the metastatic Daoy cells and 
overexpression of CD44 in the uncertain for metastasis D283 cells (Figure 23). These 
data provide further support that CD44 plays an important role in MB metastasis and 
tumor progression, and that the expression of CD44 is required for PDGFRβ regulating 
MB progression. Moreover, we also found that c-Myc is downstream from PDGFRβ 
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signaling but upstream from control of CD44 (Figure 24), which is in partial agreement 
with our microarray data from MEFs [217]. Additionally, it has been demonstrated by co-
immunoprecipitation experiments that PDGFRβ and CD44 form a complex in fibroblast 
cells [389]. 
Based on the results from this study, PDGFRα and PDGFRβ differentially regulate 
MB cellular functions via several key downstream targets such as PKCα, c-Myc, CD44, 
and NFB activity (Figure 15). Among these targets, c-Myc and CD44 play a critical 
role in PDGFRs signaling to control MB metastasis. NFB activation has been shown to 
activate c-Myc promoter in fibroblasts in response to PDGF signaling [358]; We 
demonstrated that PDGFRβ is involved in regulating the expression of c-Myc and the 
activity of NFB in MB cells and that c-Myc plays a critical role in the alterations of 
NFB activity and the expression of CD44 in MB cells in response to PDGFRβ signaling 
(Figure 15, Figure 16, Figure 17, Figure 18). 
To further decipher the molecular mechanisms along the PDGFRβ pathway that play 
vital roles in regulating MB progression, we focused our study on miRNAs. Our aim was 
to identify specific miRNAs that are differentially regulated by PDGFR and PDGFRβ. 
To achieve this goal, total RNAs extracted from Daoy cells, stably knocked down in 
either PDGFR or PDGFRβ were analyzed for differential expression of specific 
miRNAs. Microarray analysis from Exiqon provided us with two potential candidates, 
namely miR-1280 and miR-1260, along with their specific target molecules, Jagged 2 and 
CDC25A, respectively that might additionally play a part in directing PDGFRβ to its 
distinct pathway.  
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Jagged 2 is a transmembrane glycoprotein that binds to notch receptors regulating cell 
proliferation and differentiation in both normal and pathological conditions [376-381]. 
However the contribution of Notch signaling in MB development is still controversial 
[390-393], Notch signaling plays a vital role in maintaining homeostasis in stem and 
progenitor cells during embryogenesis, aberrations in which can result in MB formation 
[79, 80]. Significance of Notch signaling in MB has been demonstrated by inhibiting 
numerous Notch pathway key regulators, where a reduction in cell proliferation and an 
increase in cell apoptosis were observed [97, 101, 102]. In vivo studies have also verified 
the importance of ligand activated notch signaling in wound healing [394, 395]. 
Abnormal notch signaling initiated by Jagged 2 has also been demonstrated to play an 
important role in tumor initiation and progression in other tumor types including human 
B-cell lymphoma [395], multiple myeloma [396-398], and breast cancer [399]. All these 
studies indicate that targeting Notch signaling can be beneficial towards the treatment of 
MB. In the siRNA knockdown of either PDGFRβ or c-Myc condition, we observed a 
reverse correlation between miR-1280 and miR-1260 and their expected targets, Jagged 2 
and CDC25A, respectively (Figure 33, Figure 34, Figure 36). These results confirmed 
that Jagged 2 and CDC25A are genuine targets of miR-1280 and miR-1260, respectively. 
Notably, either miR-1280 inhibitor or miR-1260 inhibitor had less effect on cell 
proliferation but significantly enhanced cell mobility (Figure 37, Figure 38). This could 
be explained by reasoning that multiple miRNAs are involved in PDGFR and c-Myc 
activated signaling in MB cells. However, surprisingly, the effects of Jagged 2 siRNA 
showed similar effects as that obtained by miR1280 inhibitor on Daoy cell proliferation 
and migration. These data indicate that Jagged 2 is a potential therapeutic target for MB 
(Figure 39, figure 40). 
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Cell cycle is a key event for cell proliferation and tumor growth, which is tightly 
controlled by many regulators. CDC25A is one of such an important modulator that 
controls cell cycle transition from G1 to S phase with dual phosphatase activity [382-
386]. Several studies have indicated that CDC25A is an action molecule that mediates c-
Myc signaling for cell proliferation [387, 388].  In this study, we noticed that a 
correlation existed in between the expression levels of CDC25A in MB cells either at 
conditions where PDGFRβ and c-Myc were down-regulated using gene specific siRNAs 
or at conditions where miR-1260 was inhibited using specific miR-inhibitor (Figure 34, 
Figure 36). These results indicate that CDC25A is a downstream target of PDGFRβ and 
c-Myc. However, miR-1260 inhibitor showed only ~10% inhibition on MB cell 
proliferation or migration (Figure 37, Figure 38). These results suggest that PDGFRβ 
and c-Myc promote MB growth via multiple targets as indicated in the (Table 17).  
In conclusion, our results have demonstrated that PDGFRβ, not PDGFRα, plays an 
essential role in MB, and that the PDGFRβ-CD44 regulatory axis controls progression in 
MB patients. Our findings that CD44 is a downstream target of PDGFRβ signaling and c-
Myc is an important molecular mediator suggest that novel targets for the control of MB 
metastasis may lie in the co-targeting of PDGFR, c-Myc, and CD44. By co-targeting two 
vital genes in MB, we revealed that PDGFRβ and c-Myc have additive effects in 
promoting MB progression via miRNAs and their targets such as Jagged 2 and CDC25A. 
Our data indicate that blockage of PDGFRβ and c-Myc signaling in MB cells 
simultaneously will co-inhibit cell migration and cell proliferation via modulating a set of 
miRNAs and consequently down-regulating the expression of tumorigenic factors, e.g. 
Jagged 2 and CDC25A and tyrosine kinase receptors, e.g. EGFR, ERBB4. Our results 
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suggest that co-targeting of PDGFRβ and c-Myc will provide a novel therapeutic strategy 
for the treatment of metastatic MB and indicate that Jagged 2 is a potential new target of 
MB. 
6.2. Overall results 
Overall, our results suggest PDGFRβ-CD44 axis and not PDGFRα regulates MB 
metastasis and also that co-inhibiting PDGFRβ and its specific downstream molecule 
PDGFRα results in an enhanced reduction of MB cell proliferation and migration. We 
demonstrated that while PDGFRβ signaling pathway induced MB cell migration and 
invasion, PDGFRα had contradictory effects. We hypothesized and confirmed that 
distinct cellular function depicted by PDGFRα or PDGFRβ is due to the specific 
downstream target molecules they regulate. In the absence of PDGFRβ we observed a 
down-regulation of important molecules like c-Myc, CD44, PKCα along with reduced 
NFB activity; however no such change was observed in the absence of PDGFRα. 
Interestingly, we found no detectable levels of CD44 in uncertain for metastasis D283 
cells when compared to metastatic Daoy cells indicating that PDGFRβ-CD44 axis plays a 
crucial role in MB metastasis. Experiments that use siRNAs demonstrating knockdown 
effects appear minor due to a couple of reasons such as the short half-life of siRNAs in 
the medium and also the doubling time of the cells that decrease the efficiency of the 
siRNAs [400]; also because D283 cells are non-adherent cells. In vitro invasion assay 
using CD44 overexpressed D283 cells and CD44 knock down Daoy cells reinforced that 
PDGFRβ-CD44 axis controls metastasis in MB. We also observed that c-Myc acts as an 
intermediary molecule between PDGFRβ and CD44; while it is regulated by PDGFRβ, it 
regulates the expression of its downstream molecule CD44. 
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Figure 41. A panel of the proposed model. The panel depicts the PDGFRβ pathway 
specifically regulating c-Myc which then either regulates (a) CD44, an important 
molecule for MB invasion or (b) miR-1280, which then inhibits its target molecule 
Jagged 2, a vital molecule for MB cell proliferation and migration. Targeting this 
alternative pathway can hence be a potential therapeutic strategy in the treatment of MB. 
Co-inhibiting PDGFRβ and c-Myc by both specific siRNA and inhibitor molecules 
exhibited additive inhibitory effect on MB cell proliferation and migration. These results 
suggested that for both targeted therapy and pharmacologically, co-inhibiting PDGFRβ 
and c-Myc might provide a novel therapeutic strategy for the treatment of MB. Our 
search on targeted inhibitory therapy intrigued us to further study the mechanisms in the 
PDGFRβ signal pathway that bring about this additive effect; the results revealed 
miRNAs, miR-1280 and miR-1260, that are regulated by both PDGFRβ and c-Myc, 
which in-turn regulate the expression of their target molecules such as Jagged 2 and 
CDC25A respectively in MB. We also observed that specific knockdown of Jagged 2 
reduces MB cell proliferation and migration indicating that Jagged 2 plays a role in MB 
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progression. These molecules pose as potential therapeutic targets for MB inhibitory 
therapy. 
To summarize, our study has contributed in identifying a distinct signal cascade 
initiated by PDGFRβ, followed by c-Myc and CD44. In parallel we also identified that 
both PDGFRβ and c-Myc regulate miR-1280, and miR-1280 regulates the expression of 
Jagged 2. All these data might assist in providing a novel therapeutic strategy for the 
treatment of MB.  
6.3. Clinical implications and future directions 
 Several studies have demonstrated that PDGFRs are overexpressed in MB and that 
they are vital for tumor progression [117, 118]. It has also been shown that PDGFR 
inhibition reduces cell proliferation [115, 116, 214]. Our study presented that PDGFRβ 
instead of PDGFRα induce cell proliferation via c-Myc and regulate metastasis via CD44 
in MB. Hence targeting PDGFRβ signal pathway to treat MB patients can be more 
beneficial for prolonged survival. Earlier results have demonstrated that while PDGFRαα 
specifically phosphorylates Crk molecules and RasGAP is specifically phosphorylated by 
PDGFRββ [331-333].  In-depth study of these molecules and their pathway might assist 
in deciphering the distinct functions played by PDGFRα and PDGFRβ in MB. Discovery 
of novel drugs specifically targeting PDGFRβ can distinctly limit MB cell migration and 
invasion. SJ001 is one such PDGFR inhibitor identified in our lab that has shown a great 
potential in inhibiting MB cell growth [214]. Also, in vivo studies by knocking out either 
PDGFRα or PDGFRβ to measure the effect on tumor progression can be performed to 
further elucidate the specific functions in MB.  
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Furthermore, study of specific downstream molecule like CD44, specifically 
regulated by PDGFRβ, has exhibited its crucial role in MB metastasis. Also, physical 
interaction between PDGFRβ and CD44 has been demonstrated in the fibroblast cells 
[389]. CD44 is a cell surface adhesion protein which has been linked to metastasis in 
numerous cancer forms [349, 354, 356, 357]. In vivo studies have also demonstrated 
down-regulation in metastasis by knocking down CD44 [401, 402]. In our studies we 
noticed that overexpressing CD44 in uncertain for metastasis MB cells induced them to 
have increased invasive ability when compared to control cells. By knocking out CD44 
and measuring tumor metastasizing to other organs by in vivo studies can be performed to 
confirm that CD44 plays a crucial role in MB metastasis. Also, to further confirm the 
importance of CD44 in Mb CD44-expressing cell lines such as ONS76 and UW228 can 
be used to knockdown CD44 and check for the invasion in vitro [403, 404]. 
Simultaneously, non-adherent cell lines just like D283 such as D341 and D425 can be 
analyzed further for the baseline expression of CD44 [338, 405]; and overexpress CD44 
if undetectable levels of CD44 are obtained to check for the change in their invasive 
abilities caused by CD44. Hence, targeting CD44 can prove to be beneficial in the 
treatment of MB. 
In our results we identified that c-Myc regulates CD44 by interacting with its 
promoter region, thereby regulating MB invasion via CD44. We also demonstrated that 
by inhibiting c-Myc, MB cell proliferation reduces significantly. Co-inhibition of c-Myc 
along with PDGFRβ exhibited an additive inhibitory effect on both cell proliferation and 
migration both by using siRNAs and inhibitors. Co-inhibition experiments also verified 
that both PDGFRβ and c-Myc molecules regulate Jagged 2 and CDC25A in MB. This 
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result indicates that co-targeting two important molecules like PDGFRβ, which is crucial 
for MB cell migration, and c-Myc, which plays a vital role in MB cell proliferation, can 
provide an alternative approach and a better therapeutic strategy in the treatment of MB.  
To further elucidate the mechanism by which PDGFRα and PDGFRβ induce distinct 
signal pathways in MB, we performed miRNA profiling in the absence of either 
PDGFRαr PDGFRβ. Few miRNAs such as miR-1280 and miR-1260 were identified that 
were differentially regulated by either of the receptors. Similarly, to identify specific 
miRNAs regulated by both PDGFRβ and c-Myc we performed miRNA profiling in 
PDGFRβKD, c-MycKD and PDGFRβKDc-MycKD cells. Interesting ~30 different miRNAs 
were identified, of which two were miR-1280 and miR-1260. Specific inhibition of these 
miRNAs demonstrated mainly two things, they regulate MB cell proliferation and 
migration and also that miR-1280 targets Jagged 2 and miR-1260 targets CDC25A 
specifically.  
Jagged 2 is an important ligand that binds to notch receptor to induce notch signaling 
[378, 381]. Notch signaling is a crucial pathway during embryogenesis, aberrations in 
which can induce MB formation [79, 89, 95]. Our study demonstrated that specific 
knockdown of Jagged 2 resulted in down-regulation of both MB cell proliferation and 
migration. This data clearly indicates that Jagged 2 is a potential therapeutic target in 
MB.  
 The information gained from our study provides new insights into the possible 
mechanisms by which PDGFRs regulate MB metastasis and progression. It also provides 
us with novel therapeutic strategies in the treatment of MB. To our knowledge, this is the 
first study that indicates PDGFRβ-CD44 axis to control metastasis in MB and co-
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targeting PDGFRβ and c-Myc to provide enhanced inhibition of MB cell progression via 
Jagged 2.  
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